
==== Front
Chin Med
Chin Med
Chinese Medicine
1749-8546
BioMed Central London

988
10.1186/s13020-024-00988-w
Review
Targeting lipid droplets and lipid droplet-associated proteins: a new perspective on natural compounds against metabolic diseases
Jiang Xinyue 1
Wang Hongzhan 1
Nie Kexin 1
Gao Yang 1
Chen Shen 1
Tang Yueheng 3
Wang Zhi 2
Su Hao 2
Dong Hui tjhdonghui@163.com

1
1 grid.33199.31 0000 0004 0368 7223 Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 grid.33199.31 0000 0004 0368 7223 Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 grid.33199.31 0000 0004 0368 7223 Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 9 2024
4 9 2024
2024
19 12017 6 2024
22 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Lipid droplet (LD) is a metabolically active organelle, which changes dynamically with the metabolic state and energy requirements of cells. Proteins that either insert into the LD phospholipid monolayer or are present in the cytoplasm, playing a crucial role in lipid homeostasis and signaling regulation, are known as LD-associated proteins.

Methods

The keywords “lipid droplets” and “metabolic diseases” were used to obtain literature on LD metabolism and pathological mechanism. After searching databases including Scopus, OVID, Web of Science, and PubMed from 2013 to 2024 using terms like “lipid droplets”, “lipid droplet-associated proteins”, “fatty liver disease”, “diabetes”, “diabetic kidney disease”, “obesity”, “atherosclerosis”, “hyperlipidemia”, “natural drug monomers” and “natural compounds”, the most common natural compounds were identified in about 954 articles. Eventually, a total of 91 studies of 10 natural compounds reporting in vitro or in vivo studies were refined and summarized.

Results

The most frequently used natural compounds include Berberine, Mangostin, Capsaicin, Caffeine, Genistein, Epigallocatechin-3-gallate, Chlorogenic acid, Betaine, Ginsenoside, Resveratrol. These natural compounds interact with LD-associated proteins and help ameliorate abnormal LDs in various metabolic diseases.

Conclusion

Natural compounds involved in the regulation of LDs and LD-associated proteins hold promise for treating metabolic diseases. Further research into these interactions may lead to new therapeutic applications.

Graphical Abstract

Keywords

Lipid droplet
Lipid droplet-associated proteins
Metabolic diseases
Natural compounds
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China No. 82174159 Dong Hui the Fifth Batch of National Traditional Chinese Medicine Excellent Clinical Talents Training Project2022-1 Dong Hui issue-copyright-statement© International Society for Chinese Medicine and BioMed Central Ltd. 2024
==== Body
pmcIntroduction

The prevalence of metabolic diseases, including obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD), is escalating yearly, posing a serious threat to human health [1]. According to the latest epidemiology, overweight rates in adults reached 42.4% and 59% in the United States and Europe, respectively [2]. The global incidence of NAFLD has reached 32.4% by 2021 [3]. The optimal treatment for these diseases involves improving lifestyle and dietary habits, yet the outcome is poor due to a lack of patient adherence [4].

As an active organelle, lipid droplet (LD) varies dynamically with the metabolic state and energy requirements of cells. Early research established that LDs are crucial for lipid metabolism, with abnormalities often leading to lipotoxicity-related diseases, like diabetes, and fatty liver diseases [5]. LD-associated proteins, also known as LD proteins, are decorative proteins of phospholipid monolayers, including lateral proteins and gross membrane proteins which employ a single topology [6]. Primary studies of LD-associated proteins referred to classical protein families like perilipins (PLINs), which were found to prevent lipolysis of LDs [7–10]. Subsequently, more molecules are gradually being recognized as LD-associated proteins, like Cell death-induced DNA fragmentation factor 45-like effector (CIDE), hypoxia inducible gene 2 (HIG2), etc. [11, 12]. LD-associated proteins are involved in various physiological activities such as LD biogenesis, growth, fusion, and lipolysis, thus affecting lipid homeostasis [13]. Therefore, targeting the regulation of LDs and LD-associated proteins may offer novel approaches for the therapy [14].

Massive basic or clinical studies have confirmed that traditional Chinese medicine could remarkably confront metabolic disorders by improving lipid metabolism. However, traditional Chinese medicine have complex components and their pharmacological mechanism have not been thoroughly elucidated, resulting in limited application. Moreover, the potential role in regulating LDs remains unknown. The keywords “lipid droplets” and “metabolic diseases” were used to obtain literature on LD metabolism and pathological mechanisms. After searching databases including Scopus, OVID, Web of Science, and PubMed from 2013 to 2024 using terms like “lipid droplets”, “lipid droplet-associated proteins”, “fatty liver disease”, “diabetes”, “diabetic kidney disease”, “obesity”, “atherosclerosis”, “hyperlipidemia”, “natural drug monomers” and “natural compounds”, we identified the most common natural compounds in about 954 articles. Eventually, a total of 91 studies of 10 natural compounds reporting in vitro or in vivo studies were refined and summarized to elucidate the mechanism by which natural compounds affect LDs and LD-associated proteins. We aim to provide a reference for further research on the regulatory mechanism of natural compounds and their effective management of metabolic diseases.

Connection between LD dynamics and LD-associated proteins

LD primarily consists of a core formed by triacylglycerol (TAG) and cholesterol ester (CE), which are enveloped by an amphiphilic phospholipid monolayer containing numerous embedded proteins on the surface [15]. In addition to storing and regulating lipid utilization [16], LD serves as a reservoir for proteins [17]. The proteomics of LD has revealed over 200 protein components, some of them fixate only in LDs, while others are also present in other subcellular compartments [18]. As a metabolically active organelle, the size, morphology, number, lipid composition and protein composition of LD can change according to the metabolic situation of the organism. The dynamics of LD include LD biogenesis, expansion, fusion, degradation, and contacts with other cellular organelles [19]. The orderly unfolding of these processes depends on LD-associated proteins.

LD-associated proteins

Various LD-associated proteins can be generally classified according to their functions as follows: enzymes that catalyze lipid metabolism, histones that bind nucleic acids to LDs, ribosomal proteins that exist in protein synthesis in prokaryotes, proteins from protein degradation, proteins with signaling capabilities, membrane transport proteins that interact with other organelles, dynamics related proteins such as microtubules and skeletal proteins responsible for movement, LD resident proteins that are directly targeted to LDs with subcellular structural characteristics, etc. [20].

Protein targeting occurs in multiple biological processes in LD including LD biogenesis, growth, degradation, etc. Based on their targeting pathways, LD-associated proteins can be subdivided into two classes. The first class, “ERTELLED” (classical class I), consists of proteins inserted into the endoplasmic reticulum (ER) membrane that relocate to the LD surface through ER-LD contact. The second class, “CYTELLED” (classical class II), comprises proteins translated in the cytoplasm that directly target the LD surface [21, 22].

ERTELLED proteins generally comprise hydrophobic membrane-embedded sequences that acquire a hairpin configuration in the ER bilayer. This class includes esteryol coenzyme A synthase (e.g. Acyl-CoA synthetase long-chain family member 3 (ACSL3), ACSL5) [23], triglyceride lipase (e.g. adipose triglyceride lipase/Patatin-like phospholipase domain-containing protein 2 (ATGL/PNPLA2) [24], acyltransferases (e.g. GPAT4, LPCAT) [25], LD-associated hydrolase [26], LD assembly factor 1 (LDAF1, also known as TMEM159) [27], and UBX structural domain-containing protein 8 (UBXD8) [28], etc.

CYTELLED proteins are soluble proteins with several LD-binding amphipathic helix motifs, including the PLIN family, comparative gene identification-58 (CGI-58, also known as ABHD5) and Phosphocholine cytidylyltransferase (PCYT or CCT) [29–31]. Among these, the PLINs are the main LD-associated proteins [32]. PLIN1 and PLIN4 are mainly expressed in White adipose tissue (WAT). PLIN5 is generally expressed in the liver, heart, BAT and skeletal muscle. Meanwhile, PLIN2 and PLIN3 are widely expressed in various tissues [33].

LD Biogenesis

Present studies supposed that the synthesis of neutral lipids plays a major part in LD biogenesis. The neutral lipids synthesis from activated fatty acids (FAs) represents the first step of LD biogenesis. If FA esters to diacylglycerol (DAG), it is further catalyzed by diacylglycerol acyltransferases to produce TAG. Similarly, if FA esterifies to sterols (e.g. cholesterol), they are catalyzed by cholesterol o -acyltransferases to CE afterward [34].

ER-LD contact is known to make sense for LD formation [35]. Seipin, an ER protein that mediates ER-LD contacts, determines the site where LDs form in the ER and interacts with LDAF1 to form the LDAF1-Seipin complex [36]. The complex co-purifies with TAG, followed by TAG elution by membrane phospholipids, forming LDs [37]. After LD formation, LDAF1 splits from Seipin, turning to the LD surface. While lacking the complex, only high levels of TAG (4% or above) can facilitate LD formation [38]. Seipin also works as a scaffolding protein to recruit enzymes like 1-acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2) and lipoprotein 1 (Lipin-1), and restrains palmitic acid (PA) levels by reducing Glycerol-3-phosphate acyltransferase (GPAT) [39, 40] (Fig. 1).Fig. 1 LD biogenesis. Activated fatty acids produce neutral lipids in TAG synthesis. Wrapped by the phospholipid molecule shell deriving from the ER leaflets, the neutral lipids sprout into oil lenses and grow larger. When the superficial tension attains a certain level, the budding LD flips form a mature LD

Nucleus LDs (nLDs) are commonly found in cultured cells of liver and hepatic origin [41, 42], with a higher ratio of CE and TAG compared to cytoplasmic LDs (cLDs). Interestingly, although Seipin is an essential protein for cLD formation, the knockdown of Seipin may increase the amount of nLDs in the experimental strains instead [43].

LD growth

After initial biogenesis, LD tends to expand by fusion between LDs and local lipid synthesis (Fig. 2A). LD fusion occurs through LD-LD coalescence or LD-LD lipid transfer [44]. LD coalescence occurs when the stability of phospholipid monomolecular membrane of LDs decreases due to a reduction in phosphatidylcholine (PC) or the aggregation of fusogenic PA [31]. Phosphocholine cytidylyltransferase (PCYT or CCT) is a key rate-limiting enzyme in the Kennedy pathway of PC synthesis. Among them, PCYT1A (CCT1) can be transported directly from the cytoplasm to the surface of LDs [45]. The knockdown of PCYT1A results in increased production of LDs, while its activation promotes the maintenance of LD homeostasis [31, 46].Fig. 2 LD growth and LD degradation. A 1. When LDs contact with ER, adipogenic enzymes catalyze the TAG synthesis. 2&3. Both LD fusion and lipid transfer between LDs render the growth. B 1. Macroautophage is the process of formation of autophagosome by double-membrane vacuoles before fusion with lysosomes. 2. Chaperon-mediated autophagy (CMA) refers to lysosomal selective capture of LDs containing the KFERQ motif. 3. Direct lysosomal degradation of LDs is microautophagy

CIDE can moderate the formulation of oversized LDs in adipocytes by mediating LD-LD lipid transfer. CIDEs locate to LDs through a carboxy-terminal amphiphilic helix to generate a dimer. The dimer diffuses on the LD surface and engages with another LD containing CIDE. The presence of CIDE on both LD surfaces promotes the formation of stable trans-organelle oligomers, which provide channels for lipid transfer [47]. This process allows neutral lipids to migrate from smaller LDs to larger LDs, while protein transfer does not occur [48]. In human hepatocytes, CIDEB promotes TAG transfer, but this catalytic role relies on the expression of CIDEC or CIDEA [49].

In addition, neutral lipid synthase-mediated local lipid synthesis is involved in the growth of LDs. The previously mentioned membrane bridge in LD-ER contact enables adipogenic enzymes like diacylglycerol acyltransferase 2 (DGAT2) and GPAT4 from ER to the LD surface, catalyzing the local synthesis of neutral lipids [50]. Lipin-1 (also known as PAH1) with phosphatidic acid phosphatase (PAP) activity, co-localizing with other proteins like PLIN2 and PLIN3, catalyzes PA into DAG [51]. Eventually, LD formation arises at the ER-LD interface [52].

Contacts with other organelles

Recent research has revealed that LDs inevitably come into contact with other organelles when performing biological functions, through the fusion with phospholipid monolayers and variations of LD-associated proteins [53, 54]. LD-ER contact triggers LD generation and LD-associated protein targeting; LD-LD contact causes LD enlargement; LD-nuclear membrane contact lays the basis for nLD formation; LD-lysosome contact provides conditions for autophagy. In addition, LDs also seem to contact with mitochondria and peroxisome.

During nutrient deprivation, LD-mitochondrial contact function as sites of lipogenesis or catabolism [55, 56]. Although the specifies of LD-mitochondrial haven’t been clarified yet, studies have found that PLIN5 overexpression in BAT to induces mitochondrial recruitment at the LD periphery [57], and PLIN1 interacts with mitochondrial protein 2 [58]. A recent review summarized LD-associated protein interactions that mediate LD-mitochondrial contact: PLIN5-fatty acid transporter protein (FATP4) and Mitofusin2 (MFN2)-Heat shock cognate 71 kDa protein (HSC70)-PLIN1 for fatty acid oxidation; ADP-ribosylation factor related protein 1 (ARFRP1)-Synaptosome-associated protein 23 (SNAP23) and mitoguardin 2 (MIGA2)-Vacuolar Protein Sorting 13D (VPS13D) for LD growth [59].

Similar to the function of mitochondria, the peroxisome is the only setting of β -oxidation in yeast, along with branched-chain fatty acids and β -oxidation of very long-chain fatty acids in humans [60]. The molecular basis for the fusion between the outer layer of peroxisomal phospholipid leaflets and the LD membrane still requires clarification [61].

LD degradation

LD degradation frequently occurs, though not exclusively, following the completion of biological processes. The most common form of degradation for LDs is lipolysis, which requires ATGL /PNPLA2 and its activator CGI-58, hormone-sensitive triglyceride lipase (HSL), and monoacylglycerol lipase (MAGL) [62–64], etc. Moreover, ATGL is activated via the patatin structural domain interacting with CGI-58, as well as inhibited by CIDEC. During nutrient deprivation, LDs can also degrade by lipophagy, a selective autophagic procedure that transports part or the entire LDs to lysosomes, undergoing bulk degradation by hydrolytic enzymes [65].

The PLIN family, governed by sterol regulatory element binding protein (SREBP), liver X receptor (LXR) and peroxisome proliferators-activated receptor (PPAR), affects LD degradation by regulating the efficiency of lipase entry to the surface of LDs [66]. For instance, chaperone-mediated autophagy (CMA) degradation of PLIN2/3 promotes the entry of ATGL and autophagy proteins into the surface of LDs. The Rab proteins, consisting of around 70 small GTPases, modulate cytoskeletal motility and are also involved in the autophagic process [67]. Rab7 regulates the interaction between lysosomes and autophagosomes through members of the homotypic fusion and protein sorting (HOPS) tethering complex and soluble NSF attachment protein receptor (SNARE) proteins [68] (Fig. 2B).

The role of LDs in relevant diseases

LDs play a vital part in lipid metabolism and signaling pathways. Abnormalities of LD-associated proteins leads to dysregulation of LD dynamics, resulting in significant disorders (Fig. 3). The available evidence indicates that LDs and LD-associated proteins are closely related to metabolic diseases.Fig. 3 Abnormal LD formation in metabolism-related diseases. The FASN-mediated lipid synthesis system and CIDE-mediated LD fusion promote the generation of giant LDs. Moreover, the expression of ATGL, CGI8, Rab7/18, ACOX, CPT1, ABCA1, and ABCG1 is downregulated, inhibiting lipolysis and β-oxidation, resulting in LD deposition

Metabolic diseases

NAFLD, is a spectrum of chronic liver diseases that includes simple hepatic steatosis, nonalcoholic steatohepatitis, fibrosis and cirrhosis [69]. During steatosis, excessive triglycerides are stored in LDs [70]. The continuous generation of LDs, frequent LD fusion and impaired LD autophage contribute to LD accumulation [71, 72]. Furthermore, extremely large LDs cluster in hepatocytes [73].

In mouse models, CIDEC, CIDEA and PLIN2 are highly upregulated in hepatocytes [74, 75], while the same changes of CIDEC occur in patients [76]. PLIN2 may display an anti-lipolytic impact by disrupting the action of ATGL on LDs [77]. Knockdown of PLIN5 in high-fat-diet (HFD) mice results in reduced steatosis and fibrosis in the liver, suppression of SREBP1 and its downstream fatty acid synthase (FASN),and inactivation of adenosine 5’-monophosphate-activated protein kinase (AMPK) [78]. Besides, PNPLA3 (I148M) accumulation on the LD surface may segregate CGI58, thus promoting lipolysis [79, 80]. As for the Rab family, both Rab18, which has a regulatory role in lipolysis, and Rab7, which is related to autophagy are decreased in steatotic livers [81]. Serum levels of very low-density lipoprotein (VLDL) and TAG from VLDL are reduced in mice with CIDEB loss, while TAG levels in liver are increased [82].

Diabetes is also closely related to the homeostasis of LDs. Dai et al. found that mice transplanted with human islets developed more LDs in islet cells after a HFD [83], while hypertrophic LDs stack in adipocytes [59]. Hyperglycemia induce a significant fraction of lipophagy, ultimately resulting in LD accumulation and inflammation [84]. Similarly, renal biopsies from patients with diabetic nephropathy (DN) showed increased lipid deposition and LDs [85], which may be a compensatory protective pathway against lipotoxicity [86]. Resulting from increased PLIN2, decreased autophagic flux and excessive PPARδ activated by lysophosphatidylcholine, LD accumulation contributes to the decline in rapid renal function in DN [87].

Insulin secretion may be regulated by LD degradation. Lipolysis-generated FA promotes insulin secretion by prompting the PPARδ pathway and adenosine 5′-triphosphate production in mitochondria [88]. Local FA activates cell surface receptors (e.g. FAR1) and enhances insulin secretion [88]. Meanwhile, lipolysis-generated 1-monoacylglycerols (1-MAG) also stimulates insulin granule cytosolic action [89]. Unlike healthy people, patients with T2DM fail to undergo lipolysis induced by glucose for a currently unknown mechanism. However, present studies have confirmed that when the key enzymes for lipolysis (e.g. ATGL) become defective, palmitoylation of insulin synthesis protein 1a (STX1a) decreases, accelerating the degradation of STX1a and lowering insulin secretion [90].

Renal diseases

When acute kidney injury (AKI) occurs, there is a deficiency of AMPKα with LD accumulation in the renal tubules [91]. In the plasma of patients with primary focal segmental glomerulosclerosis, the circulating permeability factor induces LD accumulation and overexpression of PLIN2 (a marker of renal fibrosis) [92, 93]. Fibrosis in the renal interstitium features increases LDs in proximal tubular cells, and the expression of PPARα, carnitine palmitoyltransferases 1 (CPT1), acyl-Coenzyme A oxidase 1 (ACOX1), PPARγ coactivator 1α (PGC-1α), and fatty acid binding protein 4 (FABP4) elevates [94].

AKI is a substantial risk for the occurrence and development of chronic kidney disease (CKD) [95]. In CKD models, the expression levels of CPT1, ACOX1, and L-FABP decrease significantly [96, 97]. Instead, the expression levels of LDL receptor (LDLR) and SREBP-2 increase significantly [96, 97]. CPT1, ACOX1, and L-FABP are the crucial proteins in fatty acid β-oxidation pathway, while LDLR and SREBP-2 are associated with cholesterol uptake. Reduced catabolism and excessive sterol intake result in enhanced neutral lipid content from LDs and eventually lead to the formation of giant LDs [98, 99].

Cardiovascular diseases

In atherosclerosis (AS), lipids, primarily CE, increase the phagocytic load of macrophages, leading to the formation of more foam cells. Compared to normal areas of arteries at the same level, the high expression of PLIN2 in plaques induces the overexpression of pro-inflammatory cytokines [100, 101]. Additionally, PLIN2 aggravates the accumulation of CE in macrophages by restricting cholesterol efflux [102]. CIDEB-knockout mice show reduced plasma LDL and cholesterol levels, but increased liver cholesterol, which may result from the increased expression of LDLR and Acyl coenzyme A-cholesterol acyltransferase (ACAT1) [103]. Although HSL has a broad substrate specificity, it vanishes in human AS progression [104].

Clinical studies have shown that PLIN5 increased during heart attacks, similar to the high-sensitivity cardiac troponin I, thus may serve as a biomarker [105]. In addition, PLIN5, previously mentioned, functions in mediating LD-mitochondria contact, may provide new avenues for the therapy of myocardial ischemia–reperfusion injury (IRI). In the mouse models, inhibition of PLIN5 can promote cardiomyocyte proliferation and activate the PPAR signaling pathway, reduce the expression of PPARγ but raise the expression of PPARα [106]. Above all, increased PLINs may be the reason for more LDs, while various lipotoxic intermediates leading to excessive deposition of LDs in vesicles in the myocardium and eventually causing cardiac steatosis [107].

Cancer

Lipid mobilization of LDs provides additional energy for drastically proliferating cancer cells: the FAs from core catabolism enter the mitochondria for oxidative energy supply [108]. LDs can also ensure cancer cell survival by reducing lipotoxicity via storing excess lipids in the inflammatory microenvironment [109]. ACSL4 can increase the contents of TAG and LDs in hepatocellular carcinoma cells [110]. ACSL3, which is required for exogenous fatty acid lipogenesis, expresses more to induce LD accumulation in renal cell carcinoma [111–113]. The synthesis of TAG, along with CIDEC and PLIN3, appears to be highly expressed with the decrease of CIDEB. The lipogenic proteins like ACSL4 and ACSL4 are upregulated, while CIDEB involved in TAG transfer is downregulated, which ultimately results in LD accumulation. What’s more, LDs may remove misfolded proteins by regulating fatty acids, the mechanism of which remains to be investigated [114].

LD-associated proteins have diagnostic, therapeutic and prognostic values in cancer [115], as exemplified by PLINs. PLIN2 has enhanced expression in urological cancers [116], and also has reference in the diagnosis of breast cancer staging and colorectal cancer [117, 118]. PLIN1 has potential to inhibit breast cancer [119]. PLIN4 overexpresses in adriamycin-resistant cells, which can be targeted to eliminate chemoresistance [119].

Other diseases

Congenital lipodystrophy (CGI) is a group of heterogeneous disorders defined by a particular lack of fatty tissue with ectopic steatosis, dyslipidemia, and insulin resistance (IR) [120]. The supplementation of leptin may alleviate related symptoms. CGI is a scarce autosomal recalculant disease, relevant to the gene deletions of AGPAT2 (BSCL1), Seipin [121].

Some common pathogens usually metabolize by means of LDs in host cells. The hepatitis B virus invokes hepatic steatosis in the mouse model by targeting its core protein to LDs and enhancing LD-ER contact. This is achieved through NS5A binding to Rab18, which promotes LD generation and LD-associated protein targeting [122, 123]. Knockdown of PLIN3 attenuates this steatosis [124]. In addition to mediating pathogen infection, LDs also play an immunological role. For instance, the translation of viperin (an innate immune protein) posts on LDs [125].

Links between natural compounds and LDs

Studies on natural compounds associated with lipid regulation have mainly focused on signaling pathways like AMPK, mammalian target of rapamycin (mTOR) and PPAR. Some downstream targets of these signaling pathways, which are involved in lipid metabolism, are also discovered to be localized on LDs. These targets including GPAT4, DGAT1, DGAT2, CPT1, and ATGL, are regarded as LD-associated proteins [53, 54, 126, 127]. Exploring the connection between natural compounds and LDs is of great significance for their clinical use and further development. Based on the current studies, we have summarized the mechanisms of lipid-lowering and regulation of LD homeostasis by natural compounds from the perspective of LD-associated proteins. We aim to provide new references for the clinical utilization and development of theses natural compounds (Table 1).Table 1 Natural compounds acting on LD-associated proteins

Natural compounds	Model	Positive control	Usage	Dosage & Duration	Functions upregulate downregulate	Refs	Changes to LD(Lipid)	
BBR	C57BL/6 J mice	–	I.G	300 mg/kg/day for 4 wk	–	Liver: SCD1, FASN	Zhu X et al. [129]	Content↓

Number↓

Surface area↓

	
C57BL/6 J mice	ROT	P.O	1.4 g/kg mixed with HFD for 5mons	Liver: pACC	Liver: SCD1, FABP1, CD36, CPT1a,	Yu M et al. [130]	
Black sea bream	–	P.O	50 mg/kg mixed with HLD for 8 wk[3 times daily]	Liver: LPL, HSL CPT1	Liver: ACCα, 6-PGD	Wang L et al. [131]	
ApoE-/-mice	Atorvastatine	P.O	25, 50 mg/kg mixed with HFD for 6 wk	–	Endothelial: ASCL4	(Yang Hong et al., 2024) [238]	
3T3-L1 cells	–	–	25, 50, 100 μM for 8 days	HSL, ATGL, pACC, ACSL1	FASN, FABP4	Sim MO et al. [137]	
	HepG1 cell	–	-	20 μM for 24 h	–	SCD1, FASN	Zhu X et al. [129]	
	Hepatocytes	–		1,2,4 μmol/L for 24 h	–	SCD1, CD36, CPT1a	Yu M et al. [130]	
	Cancer cells	–	–	From 6.25 to 50 μM for 24, 48, 72 h	–	FASN	Liu YX et al. [133]	
	Wistar rats	–	P.O	50, 100, 150 mg/kg BW/d mixed with HLD for 6 wk	Liver: CD36, CPT1, pACC	Liver: DGAT2	Niu Y et al. [140]	TG↓

FFA↓

	
	Syrian hamsters	–	P.O	50, 150 mg/kg BW mixed with HFD for 8 wk	Liver: CD36, CPT1

Muscle: CPT1

	Liver: ACC	Guo F et al. [141]	
	KK-Ay mice	–	I.G	100,200 mg/kg/d for 4 wk	Liver: CPT1	Liver: FASN	Li J et al. [144]	
	Male Wistar rats	–	I.G	100,200 mg/kg/d for 8 wk	Liver: CD36	Liver: DGAT2	Zhang et al. [243]	
	Male SD rats	–	I.G	50 mg/kg/d for 30 d	–	(pre)-adipocytes: SCD1	(Ying-Hao Hu et al., 2021) [239]	
MGF	HepG2 cells		–	12.5, 25, 50, 100 µmol/L for 24 h	CD36, CPT1, pACC	DGAT2	Niu Y et al. [140]	
HepG2 Cells	–	–	12.5, 25, 50 μM for 24 h	CPT1, CD36	–	Zhang Q et al. [140]	
HepG2 Cells	–	–	metabolites of MGF	Liver: ACC, ATGL, CPT1, HSL	–	Li J et al. [144]	
HT29 cancer cells	–	–	400 µM blended into 0.2 mM

FFA for 24 h

	–	CPT1	Rodriguez-Gonzalez JC et al. [143]	
3T3-L1 cells	–	–	Water extracts	–	LPL	Baek J et al. [147]	
CAP	C57BL/6 J obese mice	–	Cream onto shaved abdominal skin	100 mg/d for 8wk	Liver: CPT1, CD36	Liver: ACC, FAS	Shin MK et al. [155]	Formation↓

Size↓

Surface area↓

	
C57BL/6 J mice	–	–	0.01% mixed with HFD for 24 wk	Liver: tHSL, pHSL, CPT1	–	Li Q et al. [152]	
Mesenchymal stem cells(mMSC)	–	–	10, 50, 100, 200 μM for 6 days	–	FABP4, SCD	Jeong JY et al. [153]	
3T3-L1&X9 cells	Norepinephrine	–	1 μM for 24 h	PLIN1, CIDEA, CIDEC	–	Montanari T et al. [154]	
Visceral adipose tissues	­	–	0.01% mixed with standard laboratory chow for 5 mon	HSL	–	Chen J et al. [150]	
HepG2 Cells	–	–	200 µM for 24 h	PGC-1α, CD36	ACC	Bort A et al. [151]	
CAF	Zebrafish	–	P.O	1, 2.5, 5, 8% mixed with larval food for 20 days	Liver: ACO	Liver: (FAT)/CD36, UCP2, ACC1	Zheng X et al. [160]	Content↓

Number↓

Size↓

Redistributed evenly

	
Wistar rats	­–	P.O	20, 30 mg/kg/day combined with HFD for 8 wk	Liver: CPT1	Liver: FAS, ACC	Helal MG et al. [161]	
mMSCs	–	–	0.1, 1 mM for 7 days	–	LPL	Su SH et al. [159]	
mMSCs	–	–	1 mM for 7 day	FABP4, UCP1,

PGC-1α

	–	Velickovic K et al. [163]	
GEN	SD rats	–	P.O	50 mg/kg diet for 90 days	–	Liver: FSP27	Xiao CW et al. [169]	Formation↓

Accumulation↓

	
C57BL/6 J mice	–	P.O	1, 2, 4 g/kg mixed with HFD for 12wk	–	Liver: ACC2	Kim MH et al. [167]	
Hens	–	P.O	40, 400 mg/kg mixed with HFD for 64 days	Liver: ACOT8, ACAD8	Liver: ACC, FAS	Lv Z et al. [165]	
Buffalo Rat liver cells	–	–	5,10 μM for 24 h	pACC, CPT1, ACO	GPAT, FASN, CIDEC	(Zhong H et al., 2017) [244]	
HepG2 cells	–	–	1, 10, 25 μM for 24 h	CPT1α	FASN, SCD1	Qin H et al. [166]	
EGCG	Wistar rats	–	I.G	50 mg/kg/d mixed with HFD for 100 wk	Liver: ACSL1, FABP1, CPT2	Liver: FASN, ACC1	Yuan H et al. [174]	Number↓

Accumulation↓

	
SD rats	–	I.G	80 mg/kg/d for 30 days	–	Liver: pACC,FAS	Lin L et al. [177]	
C57BL/6 J mice	–	P.O	50, 100 mg/kg mixed with HFD for 12wk	Subcutaneous Adipose: SCD1, ACC1, FAS, HSL,

ATGL, ACO2, MCAD, PGC1α

	Epididymal Adipose: ACC1, FAS, HSL,

CPT1α, UCP2

	Li F et al. [180]	
Primary mouse hepatocytes	–	–	CCK8 assay with different doses for 48 h	SCD1	FASN	Yuanyuan Z et al., [242]	
CGA	SD rats	Orlistat	P.O	50, 100, 150 mg/kg b.w. mixed with HFD for 6 wk	Liver: CPT1	Liver: pACC	H VS et al. [185]	Number↓

Density↓

From spindle-

shaped to round

	
ICR mice	–	P.O	0.2 g/kg mixed with HFD

for 8 wk

	Liver: CPT1	Liver: FAS, ACAT	Cho AS et al. [186]	
SD rats	–	I.G	60 mg/kg bw for 28 days	Liver: CPT1	Liver: FAS, ACC	Zhou Y et al. [187]	
db/db mice	Metformin	I.G	0.25 g/kg/d bw for 18 days	Liver: CPT1a, ACOX1,

ATGL HSL

	Liver: MGAT1, CD36, DGAT1/2, FATP4	Yan Y et al. [189]	
3T3-L1 cells	Rosiglitazone	–	20 μM for 10 days	HSL, DGAT1, PLIN	–	Peng SG et al. [191]	
3T3-L1 adipocytes	–	–	50 μM for 24 h	FATP	–	Maetzin Becerra Sanchez et al. [240]	
HepG2 cells	Simvastatin	–	30 μmol/L for 48 h	ABCA1	–	Shun Hao et al. [237]	
Bovine mammary epithelial cells	–	–	40 μg/mL for 48 h	–	Lipin1	Ruiyuan Yao et al. [241]	
BET	Alcohol-fed C57BL/6 J mice	–	P.O	0.5% wt/vol for 5 wk	–	Epididymal adipose tissue: HSL	Dou X et al. [196]	Content↓

Accumulation↓

Uniform deposition

of small LDs

	
Ethanol-fed Wistar rats	–	P.O	1% wt/vol ethano for 6 mon	PGC-1α	Pancreas: FAS, DGAT1/2	Yang W et al. [195]	
SD rats	–	P.O	62.5, 125, 250 mg/kg plus fructose for 5 wk	Liver: CPT1α	Liver: ADFP, CPTII, SCD1, FAS	(Ge CX et al., 2016)	
SD rats	–	I.G	1 ml/d concentration of 400 mg/kg	Liver: CPT1	–	Xu L et al. [200]	
Snout bream fingerlings	–	P.O	0.6, 1.2, 1.8% mixed with HFB for 8 wk	Liver: CPT1, MTTP	Liver: FAS	Adjoumani JY et al. [201]	
OA-induced HepG2 cells	–	–	20, 40, 80, 160 mM for 24 h	ATGL	FASN, ACC	Chen W et al. [202]	
Cells of Landes Goose fatty liver	–	–	20 mmol/L for 48 h	LPL, FABP	FAS, DGAT2	Liu J et al. [199]	
GIN	NAFLD SD rats	simvastatin	I.G	30, 60 mg/kg/day for 8 wk	Liver: CPT1, CPT2	–	Hou Y et al. [205]	Size↓

Sontent↓

Accumulation↓

	
C57BL/6 J mice	–	I.G	20 mg/kg/d for 4 wk	–	Liver: C/EBP-α, FAS, aFABP, CD68, F4/80	Gu W et al. [214]	
HFD C57BL/6 J mice	–	I.G	5, 10, 20 mg/kg for 3 wk	–	Liver: ACC, FAS, SCD1	Quan HY et al. [208]	
C57BL/6 J mice	–	I.G	30, 100, 300 mg/kg for 5 days	Liver: HSL, CES1	Liver: FAS, SCD1	Li G et al. [209]	
HFD KM mice	–	I.G	5, 10 mg/kg/d for 4 wk	WAT: HSL	WAT: C/EBPα, FAS, PLIN	Liu H et al. [215]	
3T3-L1 cells	–	–	50, 100 μM for 2 days	–	C/EBP-α, FAS, aFABP, CD68, F4/80	Gu W et al. [214]	
3T3-L1 cells	–	–	80 μM for 72 h		ACC, FAS, FABP4, PLIN	Liu H et al. [215]	
HepG2 cells	–	–	1, 10, 50,100 μM

for 8, 24, 48 h

	–	ACC-α	Lee S et al. [213]	
3T3-L1 adipocytes	–	–	20 μM for 6 days	PGC-1a, CPT1	–	Liu Z et al. [218]	
3T3-L1 adipocytes	–	–	0, 10, 20, 30, 40 µM for 8 days	pACC	FABP4, C/EBPα	Oh JM et al. [210]	
3T3-L1 cells	–	–	10, 50, 100 mM for 48 h	–	PLIN	Siraj FM et al. [217]	
RES	C57BL/6 J mice	Metformin	I.G	400 mg/kg mixed with

DMSO for 45 days

	Skeletal muscle: PLIN5	BAT, heart tissue: PLIN5	Mehdi F et al. [229]	Number↓

Size↓

Myocytes:number↑

	
C57BL/6 J mice	–	P.O	0.2% combined with

HFD for 8 wk

	–	Liver: ADFP	Nishikawa K

et al. [225]

	
C57BL/6 J mice	–	P.O	0.005%, 0.02% mixed with HFD for 6 wk	–	Epididymal WAT

Liver: FAS, PAP

	Cho SJ et al. [220]	
HFD-induced C57BL/6 J mice	–	I.G	400 mg/kg/day for 30 days	–	Liver: FSP7β, ATF6,

CREBH, PLIN1

	Zhou R et al. [222]	
HepG2 cells	–	–	5, 15, 45, 135 μmol/L plus OA for 48 h	pACC	Lipin	Tang LY et al. [223]		
OA-induced primary hepatocytes	–	–	0. 20, 50, 100 μmol/L

for 12 h

	–	PLIN, Adipophilin	Wang C et al. [224]	
FFA-induced L02 hepatocytes	–	–	20 μM for 24 h	–	FAS, ACC1, SCD1	Jing Y et al. [221]	
Stromal vascular cells	–	–	50 μmol/L for 48 h	UCP-1, CIDEA, PGC-1a	–	Wang S et al. [219]	

Berberine (BBR)

BBR (Fig. 4A), is an isoquinoline alkaloid primarily enriched in the rhizomes of Berberis spp., Coptis, and cortex of Phellodendron [128]. BBR is originally used to treat diarrhea and has since been found to have a positive therapeutic effect on glycolipid metabolism disorders. BBR can attenuate hepatic TAG accumulation caused by overnutrition through reducing the expression of stearoyl coenzyme a desaturase 1 (SCD1) [129], fatty acid uptake-related proteins (e.g. FABP1, CD36), and fatty acid oxidation-related proteins (e.g. CPT1a) via the AMPK-SREBP1c pathway [130]. Wang, et al. found that BBR intake decreased liver fat content while elevating muscle lipid accumulation in black snapper fed with an HFD. The promotion of lipid mobilization by BBR may be related to the regulation of proteins associated with stearoyl coenzyme a desaturase (ACCα) HSL, and lipoprotein lipase (LPL) [131]. Based on the studies above, by restricting SCD1/CD36-related fatty acid synthesis and enhancing HSL/LPL-related lipolysis, BBR reduces LD content by restricting the enlargement of neutral fat nuclei.Fig. 4 Chemical structures and mechanism of natural compounds. (A) BBR; (B) MGF; (C) CAP; (D) CAF; (E) GEN; (F) EGCG; (G) CGA; (H) BET; (I) GIN; (J) RES. All the chemical structures were obtained from pubchem: https://pubchem.ncbi.nlm.nih.gov/

Moreover, BBR has been reported to reduce the number and surface area of LDs in porcine oocytes at the IVM stage, stimulating miR-192 to downregulate SREBP1 and PPARγ [132]. Nevertheless, the detailed downstream effects of SREBP1 and PPARγ were not mentioned. Studies in colon cancer cells revealed that BBR inhibited lipogenesis and LD accumulation by promoting the ubiquitinated degradation of promyelocytic leukemia zinc finger-mediated SREBP-cleavage-activating protein [133]. The findings suggest that BBR may regulate LD through the PPARγ-SREBP1 pathway.

Mangostin (MGF)

MGF is a botanical isoflavone (Fig. 4B), mainly existing in Iris unguicularis, Mangifera indica, Cyclopia genitives, Salacia chinensis, Bombax ceiba and Anemarrhena asphodeloides [134]. MGF is utilized to reduce serum TAG, FA, and improve blood lipid profiles [135]. Studies in NAFLD models have shown that MGF inhibited the reactivity of ACC, DGAT2, long-chain acyl-coenzyme A synthase 1 (LACS1), and SCD1 by decreasing SREBP1c and increasing pAMPK [136–138]. As a downstream effect of AMPK, changes in ACC should be elaborated more accurately, specifically the pACC to ACC ratio [139]. Moreover, the PPARα pathway was activated following MGF treatment, resulting in increased fatty acid translocase (FAT/CD36), HSL, ATGL, LPL, CPT1 [137, 138]. Consequently, LDs in HepG2 cells and C2C12 cells declined, and FA-induced IR reduced [140, 141]. MGF promotes CPT1-related β-oxidation, and inhibites enzymes related to TAG synthesis to reduce the content of neutral fat nuclei in LDs.

An in vitro model of AS indicated that MGF increased the expression of ATP-binding cassette A1/G1 (ABCA1/G1), PPARγ, and LXRα, promoted macrophage excretion and prevented lipid accumulation [142]. Interestingly, MGF reversed the expression of metabolically active CPT1 in human HT29 colon cells, suggesting that the regulation of fatty acid β-oxidation by MGF varies across models [143]. In addition, the metabolite of MGF, desmethylthiol, reduces the levels of TAG and FA in HepG2 cells by regulating the silent information regulator of transcription 1 (SIRT-1) /AMPK pathway [144]. As regulators of lipid autophagy, PPAR and LXR regulated by MGF increase autophagy and thus decrease the number of LDs.

Capsaicin (CAP)

CAP (Fig. 4C), a phenolic compound derived from the genus Capsicum in the family Solanaceae, is a dietary agent that improves metabolism [145]. In adipocyte experiments, CAP can reduce the size and surface area of LDs by elevating pAMPK, LPL and HSL, PR structural domain containing 16 (PRDM16), CIDEA, PPARγ, uncoupling protein 1 (UCP1) [146–150]. Higher expression of pAMPK also inhibited the AKT/mTOR pathway, decreasing the basal neutrophil content in HepG2 cells [151]. The appliance of CAP in bovine bone marrow mesenchymal stem cells (BMSC) suggests that lipid deposition was inhibited during lipogenic differentiation with a lower transcription of PPARγ, FABP4 and SCD [152, 153].

The in vivo studies have demonstrated that CAP inhibits hepatic LD formation and increases plasma high density lipoprotein-C by activating transient receptor potential vanilloid 1, mediating PPAR, CPT1and CD36, and downregulating fatty acid production (e.g. ACC, FASN), which has implications for the treatment of AS and hypercholesterolemia [154–157]. It’s also worth noting that CAP cream can be given onto shaved abdominal skin, which provides a new approach for abdominal obesity. CAP mitigates LD accumulation by participating in all processes of lipid metabolism: inhibition of FABP4/SCD-related fatty acid synthesis, promotion of CPT1/CD36-related β-oxidation and lipolysis, and UCP1-mediated adipose tissue browning.

Caffeine (CAF)

CAF (Fig. 4D) is a methylxanthine that appears widely in tea trees and coffee, and clinical studies demonstrated that its consumption has a negative correlation with the level of liver fibrosis [158]. CAF lowers the amount and volume of LDs in over-nourished zebrafish larvae and reduces LD levels in rat adipose-derived stem cells through upregulating CD36, ACOX and downregulating SREBP1c, SREBP2, ACC1, PPARγ, LPL, FASN, UCP2, and SCD1) [159, 160]. The promotion of adipogenic enzymes and inhibition of PPARα induced by HFD are reversed along with higher expression of hepatic CPT1 [161, 162]. CAF inhibits the adipogenic differentiation of fibroblasts by suppressing the transcription of CCAAT/enhancer-binding protein β (C/EBPβ), PPARγ, C/EBPα in Graves, ophthalmopathy [167, 168]. As a whole, ACC1, FASN, and SCD1 are adipogenesis-related proteins, while CD36 and CPT1 are lipogenesis or β-oxidation-related proteins. They are the main targets for CAF to reduce LDs.

In addition, CAF may induce LD autophagy in hepatocytes through rapamycin complex 1 and AMPK, but the exact regulatory mechanism needs further exploration [164]. VELICKOVIC, et al. found that CAF upregulated the browning genes (e.g. UCP1, PPARγ), PRDM16, and PGC-1α in mouse mesenchymal stem cells (MSCs), with LDs becoming smaller and redistributing evenly [163]. MSCs are an in vitro model of BAT, thus the effective concentration for in vivo application requires investigation [164].

Genistein (GEN)

GEN (Fig. 4E), an isoflavone, is the major phytoestrogen in soybean. In a laying-hen FLD model, GEN inhibits the LD formation of hepatocytes [165, 166]. The expression of PPARα and its downstream ACOX, CPT1, and SREBP1c and its downstream GPAT, FASN, LXRα, ACC, and SCD1 is elevated. The expression ofFATP is downregulated [167]. Several in vitro studies also supported the ability of GEN to inhibit FA-induced LD formation in a dose-dependent manner [168].

The PPARγ-SREBP pathway may also play a role in the regulation of LDs by GEN. In the liver of non-obese rats, GEN can enhance SREBP2 and restrain SREBP1, FASN, PPARγ and its target gene CIDEC [169, 170]. It has been reported that GEN downregulate PPARγ and upregulate lipocalin by activation of estrogen receptor β and Akt/mTOR signaling, ameliorating hepatic fat accumulation [171, 172]. The downstream of pathways above requires further elaboration. CIDEC present in LD-mitochondrial contact promotes TAG transfer, while inhibiting the activity of ATGL. Lipid droplet-associated proteins, which undergo opposite alterations upon GEN intervention, are suspected to be due to differences in tissue specificity and induction models. Lipid droplet-associated proteins, which undergo opposite alterations upon GEN intervention, are suspected to be due to differences in tissue specificity and induction models. In conclusion, GEN restricts neutral fat nuclei growth by upregulating ACOX/CPT1-related lipolysis and downregulating ACC/CIDEC/SCD1-related lipogenesis.

Epigallocatechin-3-gallate (EGCG)

EGCG (Fig. 4F), is the major polyphenol and catechin in green tea [173]. EGCG attenuates liver fibrosis, hepatic LDs, glomerular necrosis and FA levels in HFD-fed mice by inhibiting cholesterol synthesis through the SREBP2/SIRT1/FOXO1 pathway [174, 175]. The activation of SREBP2 and its target gene 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) enhance cholesterol synthesis [176]. The proteomics indicated a higher expression in FATP1, ACSL1, and CPT2; but a lower expression in SREBP2 and its downstream (ACC1, FASN) [177, 178]. An in vitro study demonstrated that EGCG promoted lysosomal autophagy through a Ca2+/CaMKKβ/AMPK-dependent mechanism in vascular endothelial cells [179].

Moreover, EGCG has tissue variability when coming into effect. EGCG significantly increases the expression of lipid synthesis in WAT while relevant genes in the epithelium tissue are downregulated [180]. In contrast to the control groups, there is a decline in the abdominal lipid rate, LPL, PPARγ and hepatic lipid synthase activity (e.g. FASN, ACC), as well as an increase in ATGL and CPT1 expression [181]. Proteins related to fatty acid transport and oxidation are increased while fatty acid synthesis-related proteins are reduced, resulting in fewer LDs.

Chlorogenic acid (CGA)

CGA (Fig. 4G), a bioactive dietary polyphenol derived from tea and green coffee, can treat hepatic steatosis, cardiovascular diseases, and diabetes [182]. CGA can decrease the amount and density of LDs in liver by upregulating PPARα [183, 184]. Moreover, CGA increases pAMPK to suppress the expression of FASN, PPARγ2 and ACC [185–187]. Even so, Mubarak, A. et al. failed to favor the role of CGA in reducing lipid accumulation [188].

A study of diabetic mice showed that CGA had similar effects to metformin in reducing hepatic lipid levels by increasing ATGL, HSL, CPT1a, and ACOX1 and decreasing MGAT1, DGAT1, DGAT2, CD36, FATP4, and LPL) [189, 190]. FATP4 enlarges the core of LDs by mediating. Overall, CGA restricts LD growth by promoting ATGL-associated lipolysis and β-oxidation, and inhibiting of MGAT/DGAT/FATP-related synthesis and transport.

During 3T3-L1 preadipocyte differentiation, CGA downregulates the expression of adipocyte differentiation inhibitor gene and upregulates the expression of adipose transcription factors (e.g. CEBPB, SREBP1), differentiation-related transcription factors (e.g. PPARγ2), and lipogenic pathway-related genes (PLINs, SREBP1) [191]. Therefore, improved adipocyte differentiation changes LDs from spindle-shaped to round, while more HSL reduces intracellular TAG levels [192]. 3T3-L1 preadipocyte undergoes four differentiation stages, thus the effect of CGA in specific stages remains to be clarified [193].

Betaine (BET)

Betaine (Fig. 4H), a trimethyl derivation of glycine, presents in beets, spinach, whole grains, wheat bran [194]. Studies in rats showed that BET diminished the level of LDs and swollen mitochondria in the liver [195]. The expression of DGAT1/2, SREBP1c/2, HSL, ACC and FASN genes is significantly reduced, except for the increased mRNA level of PGC-1α, PGC-1β [196]. In alcohol-induced pancreatic steatosis, BET also reverses pathological changes like LD accumulation and elevated lipocalin levels [197]. However, preclinical models exposed to alcoholic diet cannot summarize hallmarks of human alcohol-associated liver disease (ALD) due to the complicated pathogenesis of ALD [198].

In vitro, smaller LDs deposit uniformly after BET intervention [199]. The genes of SREBP1c, SIRT1, FASN, ACC DGAT2 are downregulated, but genes of MTP, LPL, PPARα, CPT1, ATGL are upregulated [200–202]. Similarly, suppression of fatty acid synthesis and deposition, promotion of oxidation and transport by BET maintain LD homeostasis.

Ginsenoside (GIN)

GIN (Fig. 4I), the major active ingredient of Chinese ginseng, contains a group of triterpenoid saponins with different polarity (Rb1, Rg2, Rk3, Rk1, F2, etc.), which apply to IR and FA metabolism [203]. Rb1 promotes CD137, UCP1 [204], PPARα and its downstream (e.g. cholesterol 7 α-hydroxylase, CPT1α/2) in a dosage-dependent approach [205]. The activation of pAMPK (total horizontal of AMPK is unchanged) by Rb1 increases AS plaque stability by inhibiting SREBP, ACC-α, FASN, and SCD1 [206–208]. The pathways include activation of autophagic SIRT1/AMPK, PTEN/AKT, and inhibition of extracellular regulated protein kinases (ERK) /p3 and AKT [209, 210]. AKT intervenes the insulin signaling pathway, so natural compounds with insulin-like activities may regulate LDs [211].

In vitro, Rb1 downregulates the expression of FATP2, CD36, FABP1, FATP5, C/EBPβ and transcription factor PPARγ, and upregulates the expression of CPT1 and ACOX1 [212–216]. Siraj, et al. proved that F2 inhibited the mRNA levels of PLINs in adipocytes [217]. As a whole, GIN remarkably reduces LD diameter by promoting CPT1-mediated autophagy and browning-related genes, and inhibiting FA synthesis.

Resveratrol (RES)

RES (Fig. 4J), a dietary polyphenol from red wine and grapes, prevents AS and hepatic steatosis. RES reduces the number of LDs in adipocytes by increasing the expression levels of PGC-1α, UCP1, PRDM16 and CIDEA through the mTOR pathway, AMPK and ACC [218–220]. In FA-intervened human L02 hepatocytes, RES can downregulate the expression levels of SREBP1 and its target genes (e.g. SCD1, ACC1, and FAS) [221]. RES reverses the HFD-induced reduction in SIRT1 activity and elevation of—FSP27β/CIDEC, activating transcription factor 6 (ATF6), cyclic-AMP response binding protein H (CREBH), lipophilic, TIP-7 especially PLINs) [222–224]. Similarly, additional study found that RES could alleviate the expression of the adipose differentiation-related protein in the mouse liver through SIRT1/ATF6 signaling pathway [225]. SIRT1/AMPK also regulates mitochondrial autophagy [226, 227]. As a sensor of energy metabolism, SIRT1 regulates over 70 substrates like PGC-1α and Forkhead Box O (FOXO) by sensing the changes of Nicotinamide Adenine Dinucleotide (NAD+) levels [228]. Therefore, RES reduces LD accumulation by inhibiting FA synthesis and promoting adipose tissue browning.

A study on obesity found that RES attenuated the expression level of PLIN5 in BAT and heart tissue [229], while increasing the expression of PLIN5 in skeletal muscle. The clinical trial also manifested that the number of LDs in myocytes from T2DM patients increased after RES intake and LDs containing PLIN5 increased notably, but this change may help mitigate IR [230]. As a potential direct target of RES in the LD-mitochondrial contact, PLIN5 interacts with FATP, facilitating FA transfer.

Discussion

In recent years, LDs has been acknowledged as an organelle whose size, number, morphology, and composition vary dynamically in response to an individual’s metabolic state. From a physiological standpoint, LD biogenesis serves to sequester detrimental free FAs, thereby mitigating ER stress and oxidative stress induced by lipotoxicity. Disruption of LD homeostasis can result in impaired or overloaded fatty acid storage, leading to lipotoxicity-related diseases like T2DM and fatty liver. Excessive accumulation or ectopic deposition of LDs is also closely related to the pathology of cardiovascular disease, chronic kidney disease, etc. To summarize, the significant role of LDs in chronic diseases associated with lipid metabolism has been confirmed. At the same time, LD-associated proteins have also gradually attracted significant attention. This class of proteins participants in LD biosynthesis and is also the direct executor of their biological functions. Targeting LD-associated proteins to regulate the “fate” of LDs may hold great promise for the development of innovative therapies. Given that LDs exhibit dynamic changes, their state varies in different diseases or at different stages of the same disease. As such, it is crucial to flexibly regulate LD homeostasis and biological functions.

Drugs targeting LD-associated proteins are already in clinical use. DGAT2 inhibitors and ACC inhibitors can reduce liver fibrosis [231]. ACAT1 inhibitors disrupt the biogenesis of CE-rich LDs, reducing cancer proliferation and aggressiveness in prostate cancer [232]. Nonetheless, these specific inhibitors have the potential to cause harm to other regular cellular metabolic processes [54].

Natural compounds have positive prospects in the treatment of metabolic diseases due to their safety, effectiveness and multiple targets. There are numerous natural compounds with lipid-regulating, glucose-lowering, and oxidative stress-reducing effects. However, their pharmacological mechanisms are not been fully understood, limiting their potential for clinical use. We outlined the mechanism of 10 common natural compounds, focusing on the LD-associated proteins and pathways they regulate. We emphasize that LDs may be a target organelle of natural compounds, and LD-associated proteins may serve as important targets of these compounds or downstream effectors or upstream regulators of pathways (Fig. 5).Fig. 5 The effects of natural compounds on lipotoxicity-related metabolic diseases from the perspective of LD-associated proteins

Despite their potential, research on natural compounds related to LD-associated proteins remains restricted:Most studies are in vivo and in vitro studies, with a lack of clinical data.

Only phenotypic improvement and regulatory pathway data are presented, without in-depth analyses like protein interaction.

Limited focus is placed on LD-associated proteins, concentrating on PLINs and CIDEs.

Attention is mainly on LD in the liver or adipose, with less focus on cardiovascular, cerebrovascular, kidney and other organs.

Future studies should employ drug-target identification methods to focus more closely on the direct targets of natural compounds, specifically LD-associated proteins. The specific effects of natural compounds on LD-associated proteins, including post-translational modifications and protein interactions, remain unclear. As LD is a dynamically changing organelle, it is essential to understand how natural compounds regulate LD biology in different diseases or stages of the same disease. Frequent contact between LDs and other organelles can affect LD homeostasis, so it is important to investigate whether natural compounds mediate this contact.

Natural compounds also face challenges such as rapid metabolism, insufficient absorption, and poor solubility. For example, CAP has a significant first pass metabolism and a very short half-life by intravenous administration [233, 234]; BBR has poor solubility with less than 1% of oral bioavailability [235]. These drawbacks result in limitations in clinical use and dissemination [236]. As a result, the development of metabolites or derivatives from natural compounds with higher bioavailability may facilitate their clinical applications.

Conclusion

This review has summarized the current understanding of LDs, LD-associated proteins, and pathological changes arising from abnormal LD metabolism. Moreover, we provide the first overview of the therapeutic mechanisms of natural compounds with lipid-modulating effects in metabolic diseases from the perspective of LDs and LD-associated proteins.

Previous research has shown that natural compounds positively impact metabolic diseases by regulating LD homeostasis. The underlying mechanisms may be closely related to biological processes such as LD biogenesis, growth, fusion, and degradation mediated by LD-associated proteins including PLINs, CIDEs, neutral lipid synthases, lipolytic enzymes, and so on. LD deserves extensive attention as a target organelle for natural compounds. Given that natural compounds exhibit a wide range of biological activities, their therapeutic effects may also involve multiple signaling pathways. This complexity makes it difficult to elucidate whether LD-associated proteins can be direct targets of action for natural compounds with the available evidence. As a novel research target for this class of drugs, there is a need to accurately identify more LD-associated proteins, and provide more reliable and direct evidence of drug-target interactions. Challenges remain to improve the bioavailability of natural compounds and to conduct relevant clinical trials. All in all, future studies on LD and LD-associated proteins will hold promising prospects for the development and utilization of natural compounds.

Abbreviations

LD Lipid droplet

NAFLD Non-alcoholic fatty liver disease

PLIN Perilipin

CIDE Cell death-induced DNA fragmentation factor 45-like effector

HIG2 Hypoxia inducible gene 2

TAG Triacylglycerol

CE Cholesterol ester

FA Fatty acid

DAG Diacylglycerol

ER Endoplasmic reticulum

LDAF1 LD assembly factor 1

AGPAT2 1-Acylglycerol-3-phosphate O-acyltransferase 2

Lipin-1 Lipoprotein 1

PA Palmitic acid

GPAT Glycerol-3-phosphate acyltransferase

nLD Nucleus LD

cLD Cytoplasmic LD

PC Phosphatidylcholine

PCYT Phosphocholine cytidylyltransferase

DGAT2 Diacylglycerol acyltransferase 2

PAP Phosphatidic acid phosphatase

MFN2 Mitofusin2

HSC70 Heat shock cognate 71 kDa protein

ARFRP1 ADP-ribosylation factor related protein 1

SNAP23 Synaptosome-associated protein 23

MIGA2 Mitoguardin 2

VPS13D Vacuolar Protein Sorting 13D

UBXD8 UBX structural domain-containing protein 8

CGI-58 Comparative gene identification-58

ATGL Adipose triglyceride lipase

PNPLA2 Patatin-like phospholipase domain-containing protein 2

WAT White adipose tissue

HSL Hormone-sensitive triglyceride lipase

MAGL Monoacylglycerol lipase

SREBP Sterol regulatory element binding protein

LXR Liver X receptor

PPAR Peroxisome proliferators-activated receptor

CMA Chaperone-mediated autophagy

HOPS Homotypic fusion and protein sorting

SNARE Soluble NSF attachment protein receptor

FASN Fatty acid synthase

HFD High-fat-diet

AMPK Adenosine 5'-monophosphate-activated protein kinase

VLDL Very low-density lipoprotein

T2DM Type 2 diabetes mellitus

1-MAG 1-Monoacylglycerols

STX1a Synthesis protein 1a

CKD Chronic kidney disease

CPT1 Carnitine palmitoyltransferases 1

ACOX1 Acyl-Coenzyme A oxidase 1

L-FABP L-fatty acid binding protein

LDLR LDL receptor

DN Diabetic nephropathy

AKI Acute kidney injury

PGC-1α PPARγ coactivator-1α

AS Atherosclerosis

ACAT1 Acyl coenzyme A-cholesterol acyltransferase

IRI Ischemia–reperfusion injury

ACSL Acyl-CoA synthetase long chain family member

CGI Congenital lipodystrophy

IR Insulin resistance

mTOR Mammalian target of rapamycin;

BBR Berberine;

SCD Stearoyl coenzyme a desaturase

ACCα Acetyl coenzyme carboxylase α

LPL Lipoprotein lipase

MGF Mangostin

LACS1 Long-chain acyl-coenzyme A synthase 1

ABCA1/G1 ATP-binding cassette A1/G1

SIRT1 Silent information regulator of transcription 1

PRDM16 PR structural domain containing 16

UCP1 Uncoupling protein 1

BMSC Bone marrow mesenchymal stem cell

MSCs Mesenchymal stem cells

C/EBPβ CCAAT/enhancer-binding protein β

GEN Genistein

FATP Fatty acid transporter protein

EGCG Epigallocatechin-3-gallate

HMGCR 3-Hydroxy-3-methylglutaryl-coenzyme A reductase

CGA Chlorogenic acid

ALD Alcohol-associated liver disease

ERK Extracellular regulated protein kinases

RES Resveratrol

ATF Activating transcription factor

CREBH Cyclic-AMP response binding protein H

FOXO Forkhead Box O

NAD+ Nicotinamide adenine dinucleotide

CAP Capsaicin

CAF Caffeine

BET Betaine

GIN Ginsenoside

Acknowledgements

Not applicable.

Author contributions

Xinyue Jiang: Writing-Original Draft, Conceptualization. Methodology. Hongzhan Wang: Visualization, Conceptualization. Methodology. Kexin Nie: Methodology. Yang Gao: Visualization. Shen Chen: Visualization. Yueheng Tang: Data Curation. Zhi Wang: Resources. Hao Su: Supervision. Hui Dong: Writing-Review & Editing, Supervision, Funding acquisition.

Funding

This study was supported by the National Natural Science Foundation of China (No. 82174159) and the Fifth Batch of National Traditional Chinese Medicine Excellent Clinical Talents Training Project. (Announcement from the Personnel and Education Department of the National Administration of Traditional Chinese Medicine. No. 2022–1).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Xinyue Jiang and Hongzhan Wang have contributed equally.
==== Refs
Reference:s

1. Li D Li Y Yang S Lu J Jin X Wu M Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics Biomed Pharmacother 2022 153 113290 10.1016/j.biopha.2022.113290 35724509
Li D, Li Y, Yang S, Lu J, Jin X, Wu M. Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics. Biomed Pharmacother. 2022;153:113290.35724509 10.1016/j.biopha.2022.113290
2. Boutari C Mantzoros CS A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on Metabolism 2022 133 155217 10.1016/j.metabol.2022.155217 35584732
Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133: 155217.35584732 10.1016/j.metabol.2022.155217
3. Riazi K Swain MG Congly SE Kaplan GG Shaheen AA Race and ethnicity in non-alcoholic fatty liver disease (NAFLD): a narrative review Nutrients 2022 14 21 10.3390/nu14214556
Riazi K, Swain MG, Congly SE, Kaplan GG, Shaheen AA. Race and ethnicity in non-alcoholic fatty liver disease (NAFLD): a narrative review. Nutrients. 2022;14:21.10.3390/nu14214556
4. Alferink LJM Erler NS de Knegt RJ Janssen HLA Metselaar HJ Darwish Murad S Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population Eur J Epidemiol 2020 35 11 1069 1085 10.1007/s10654-020-00627-2 32323115
Alferink LJM, Erler NS, de Knegt RJ, Janssen HLA, Metselaar HJ, Darwish Murad S, et al. Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. Eur J Epidemiol. 2020;35(11):1069–85.32323115 10.1007/s10654-020-00627-2
5. Fujimoto T Lipid droplet as an independent organelle Seikagaku 2004 76 6 578 584 15287505
Fujimoto T. Lipid droplet as an independent organelle. Seikagaku. 2004;76(6):578–84.15287505
6. Dhiman R Caesar S Thiam AR Schrul B Mechanisms of protein targeting to lipid droplets: a unified cell biological and biophysical perspective Semin Cell Dev Biol 2020 108 4 13 10.1016/j.semcdb.2020.03.004 32201131
Dhiman R, Caesar S, Thiam AR, Schrul B. Mechanisms of protein targeting to lipid droplets: a unified cell biological and biophysical perspective. Semin Cell Dev Biol. 2020;108:4–13.32201131 10.1016/j.semcdb.2020.03.004
7. Yamaguchi T PAT family: lipid droplet-associated proteins that regulate fat storage and lipolysis Seikagaku 2007 79 2 162 166 17370623
Yamaguchi T. PAT family: lipid droplet-associated proteins that regulate fat storage and lipolysis. Seikagaku. 2007;79(2):162–6.17370623
8. Chang BH Chan L Regulation of triglyceride metabolism. III. Emerging role of lipid droplet protein ADFP in health and disease Am J Physiol Gastrointest Liver Physiol 2007 292 6 G1465 8 10.1152/ajpgi.00566.2006 17194897
Chang BH, Chan L. Regulation of triglyceride metabolism. III. Emerging role of lipid droplet protein ADFP in health and disease. Am J Physiol Gastrointest Liver Physiol. 2007;292(6):G1465-8.17194897 10.1152/ajpgi.00566.2006
9. Brasaemle DL Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins stabilization of lipid droplets and control of lipolysis J Lipid Res 2007 48 12 2547 59 10.1194/jlr.R700014-JLR200 17878492
Brasaemle DL. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins stabilization of lipid droplets and control of lipolysis. J Lipid Res. 2007;48(12):2547–59.17878492 10.1194/jlr.R700014-JLR200
10. Liu MF Xu GH Function of PAT family proteins in the lipid metabolism Sheng Li Ke Xue Jin Zhan 2006 37 2 103 107 16850611
Liu MF, Xu GH. Function of PAT family proteins in the lipid metabolism. Sheng Li Ke Xue Jin Zhan. 2006;37(2):103–7.16850611
11. Gao G Chen FJ Zhou L Su L Xu D Xu L Control of lipid droplet fusion and growth by CIDE family proteins Biochim Biophys Acta Mol Cell Biol Lipids 2017 1862 1197 204 10.1016/j.bbalip.2017.06.009 28648584
Gao G, Chen FJ, Zhou L, Su L, Xu D, Xu L, et al. Control of lipid droplet fusion and growth by CIDE family proteins. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862:1197–204.28648584 10.1016/j.bbalip.2017.06.009
12. Gimm T Wiese M Teschemacher B Deggerich A Schödel J Knaup KX Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1 Faseb j 2010 24 11 4443 4458 10.1096/fj.10-159806 20624928
Gimm T, Wiese M, Teschemacher B, Deggerich A, Schödel J, Knaup KX, et al. Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1. Faseb j. 2010;24(11):4443–58.20624928 10.1096/fj.10-159806
13. Seebacher F Zeigerer A Kory N Krahmer N Hepatic lipid droplet homeostasis and fatty liver disease Semin Cell Dev Biol 2020 108 72 81 10.1016/j.semcdb.2020.04.011 32444289
Seebacher F, Zeigerer A, Kory N, Krahmer N. Hepatic lipid droplet homeostasis and fatty liver disease. Semin Cell Dev Biol. 2020;108:72–81.32444289 10.1016/j.semcdb.2020.04.011
14. Chen FJ Yin Y Chua BT Li P CIDE family proteins control lipid homeostasis and the development of metabolic diseases Traffic 2020 21 1 94 105 10.1111/tra.12717 31746121
Chen FJ, Yin Y, Chua BT, Li P. CIDE family proteins control lipid homeostasis and the development of metabolic diseases. Traffic. 2020;21(1):94–105.31746121 10.1111/tra.12717
15. Walther TC Chung J Farese RV Jr Lipid droplet biogenesis Annu Rev Cell Dev Biol 2017 33 491 510 10.1146/annurev-cellbio-100616-060608 28793795
Walther TC, Chung J, Farese RV Jr. Lipid droplet biogenesis. Annu Rev Cell Dev Biol. 2017;33:491–510.28793795 10.1146/annurev-cellbio-100616-060608
16. Olzmann JA Carvalho P Dynamics and functions of lipid droplets Nat Rev Mol Cell Biol 2019 20 3 137 155 10.1038/s41580-018-0085-z 30523332
Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019;20(3):137–55.30523332 10.1038/s41580-018-0085-z
17. Li Z Johnson MR Ke Z Chen L Welte MA Drosophila lipid droplets buffer the H2Av supply to protect early embryonic development Current Biol 2014 24 13 10.1016/j.cub.2014.05.022
Li Z, Johnson MR, Ke Z, Chen L, Welte MA. Drosophila lipid droplets buffer the H2Av supply to protect early embryonic development. Current Biol. 2014;24:13.10.1016/j.cub.2014.05.022
18. Olarte M-J Swanson JMJ Walther TC Farese RV Jr The CYTOLD and ERTOLD pathways for lipid droplet-protein targeting Trends Biochem Sci 2022 47 1 39 51 10.1016/j.tibs.2021.08.007 34583871
Olarte M-J, Swanson JMJ, Walther TC, Farese RV Jr. The CYTOLD and ERTOLD pathways for lipid droplet-protein targeting. Trends Biochem Sci. 2022;47(1):39–51.34583871 10.1016/j.tibs.2021.08.007
19. Henne M Goodman JM Hariri H Spatial compartmentalization of lipid droplet biogenesis Biochim Biophys Acta Mol Cell Biol Lipids 2020 1865 1 158499 10.1016/j.bbalip.2019.07.008 31352131
Henne M, Goodman JM, Hariri H. Spatial compartmentalization of lipid droplet biogenesis. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(1): 158499.31352131 10.1016/j.bbalip.2019.07.008
20. Zhang C Liu P The new face of the lipid droplet: lipid droplet proteins Proteomics 2019 19 10 e1700223 10.1002/pmic.201700223 30216670
Zhang C, Liu P. The new face of the lipid droplet: lipid droplet proteins. Proteomics. 2019;19(10): e1700223.30216670 10.1002/pmic.201700223
21. Olarte MJ Swanson JMJ Walther TC Farese RV Jr The CYTOLD and ERTOLD pathways for lipid droplet-protein targeting Trends Biochem Sci 2022 47 1 39 51 10.1016/j.tibs.2021.08.007 34583871
Olarte MJ, Swanson JMJ, Walther TC, Farese RV Jr. The CYTOLD and ERTOLD pathways for lipid droplet-protein targeting. Trends Biochem Sci. 2022;47(1):39–51.34583871 10.1016/j.tibs.2021.08.007
22. Roberts MA Olzmann JA Protein quality control and lipid droplet metabolism Annu Rev Cell Dev Biol 2020 36 115 139 10.1146/annurev-cellbio-031320-101827 33021827
Roberts MA, Olzmann JA. Protein quality control and lipid droplet metabolism. Annu Rev Cell Dev Biol. 2020;36:115–39.33021827 10.1146/annurev-cellbio-031320-101827
23. D'Aquila T Sirohi D Grabowski JM Hedrick VE Paul LN Greenberg AS Characterization of the proteome of cytoplasmic lipid droplets in mouse enterocytes after a dietary fat challenge PLoS ONE 2015 10 5 e0126823 10.1371/journal.pone.0126823 25992653
D’Aquila T, Sirohi D, Grabowski JM, Hedrick VE, Paul LN, Greenberg AS, et al. Characterization of the proteome of cytoplasmic lipid droplets in mouse enterocytes after a dietary fat challenge. PLoS ONE. 2015;10(5): e0126823.25992653 10.1371/journal.pone.0126823
24. Smirnova E Goldberg EB Makarova KS Lin L Brown WJ Jackson CL ATGL has a key role in lipid droplet/adiposome degradation in mammalian cells EMBO Rep 2006 7 1 106 113 10.1038/sj.embor.7400559 16239926
Smirnova E, Goldberg EB, Makarova KS, Lin L, Brown WJ, Jackson CL. ATGL has a key role in lipid droplet/adiposome degradation in mammalian cells. EMBO Rep. 2006;7(1):106–13.16239926 10.1038/sj.embor.7400559
25. Moessinger C Kuerschner L Spandl J Shevchenko A Thiele C Human lysophosphatidylcholine acyltransferases 1 and 2 are located in lipid droplets where they catalyze the formation of phosphatidylcholine J Biol Chem 2011 286 24 21330 21339 10.1074/jbc.M110.202424 21498505
Moessinger C, Kuerschner L, Spandl J, Shevchenko A, Thiele C. Human lysophosphatidylcholine acyltransferases 1 and 2 are located in lipid droplets where they catalyze the formation of phosphatidylcholine. J Biol Chem. 2011;286(24):21330–9.21498505 10.1074/jbc.M110.202424
26. Kory N Grond S Kamat SS Li Z Krahmer N Chitraju C Mice lacking lipid droplet-associated hydrolase, a gene linked to human prostate cancer, have normal cholesterol ester metabolism J Lipid Res 2017 58 1 226 235 10.1194/jlr.M072538 27836991
Kory N, Grond S, Kamat SS, Li Z, Krahmer N, Chitraju C, et al. Mice lacking lipid droplet-associated hydrolase, a gene linked to human prostate cancer, have normal cholesterol ester metabolism. J Lipid Res. 2017;58(1):226–35.27836991 10.1194/jlr.M072538
27. Castro IG Eisenberg-Bord M Persiani E Rochford JJ Schuldiner M Bohnert M Promethin is a conserved seipin partner protein Cells. 2019 8 3 10.3390/cells8030268
Castro IG, Eisenberg-Bord M, Persiani E, Rochford JJ, Schuldiner M, Bohnert M. Promethin is a conserved seipin partner protein. Cells. 2019;8:3.10.3390/cells8030268
28. Suzuki M Otsuka T Ohsaki Y Cheng J Taniguchi T Hashimoto H Derlin-1 and UBXD8 are engaged in dislocation and degradation of lipidated ApoB-100 at lipid droplets Mol Biol Cell 2012 23 5 800 810 10.1091/mbc.e11-11-0950 22238364
Suzuki M, Otsuka T, Ohsaki Y, Cheng J, Taniguchi T, Hashimoto H, et al. Derlin-1 and UBXD8 are engaged in dislocation and degradation of lipidated ApoB-100 at lipid droplets. Mol Biol Cell. 2012;23(5):800–10.22238364 10.1091/mbc.e11-11-0950
29. Saka HA Thompson JW Chen YS Dubois LG Haas JT Moseley A Chlamydia trachomatis infection leads to defined alterations to the lipid droplet proteome in epithelial cells PLoS ONE 2015 10 4 e0124630 10.1371/journal.pone.0124630 25909443
Saka HA, Thompson JW, Chen YS, Dubois LG, Haas JT, Moseley A, et al. Chlamydia trachomatis infection leads to defined alterations to the lipid droplet proteome in epithelial cells. PLoS ONE. 2015;10(4): e0124630.25909443 10.1371/journal.pone.0124630
30. Čopič A Antoine-Bally S Giménez-Andrés M La Torre GC Antonny B Manni MM A giant amphipathic helix from a perilipin that is adapted for coating lipid droplets Nat Commun 2018 9 1 1332 10.1038/s41467-018-03717-8 29626194
Čopič A, Antoine-Bally S, Giménez-Andrés M, La Torre GC, Antonny B, Manni MM, et al. A giant amphipathic helix from a perilipin that is adapted for coating lipid droplets. Nat Commun. 2018;9(1):1332.29626194 10.1038/s41467-018-03717-8
31. Krahmer N Guo Y Wilfling F Hilger M Lingrell S Heger K Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase Cell Metab 2011 14 4 504 515 10.1016/j.cmet.2011.07.013 21982710
Krahmer N, Guo Y, Wilfling F, Hilger M, Lingrell S, Heger K, et al. Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase. Cell Metab. 2011;14(4):504–15.21982710 10.1016/j.cmet.2011.07.013
32. Itabe H Yamaguchi T Nimura S Sasabe N Perilipins: a diversity of intracellular lipid droplet proteins Lipids Health Dis 2017 16 1 83 10.1186/s12944-017-0473-y 28454542
Itabe H, Yamaguchi T, Nimura S, Sasabe N. Perilipins: a diversity of intracellular lipid droplet proteins. Lipids Health Dis. 2017;16(1):83.28454542 10.1186/s12944-017-0473-y
33. Filali-Mouncef Y Hunter C Roccio F Zagkou S Dupont N Primard C The ménage à trois of autophagy, lipid droplets and liver disease Autophagy 2022 18 1 50 72 10.1080/15548627.2021.1895658 33794741
Filali-Mouncef Y, Hunter C, Roccio F, Zagkou S, Dupont N, Primard C, et al. The ménage à trois of autophagy, lipid droplets and liver disease. Autophagy. 2022;18(1):50–72.33794741 10.1080/15548627.2021.1895658
34. Olzmann JA-O Carvalho PA-O Dynamics and functions of lipid droplets Nat Rev Mol Cell Biol. 2019 20 3 10.1038/s41580-018-0085-z 30479375
Olzmann JA-O, Carvalho PA-O. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019;20:3.30479375 10.1038/s41580-018-0085-z
35. Cao Z Wang X Huang X Mak HY Are endoplasmic reticulum subdomains shaped by asymmetric distribution of phospholipids? Evidence from a C elegans model system Bioessays 2021 43 1 e2000199 10.1002/bies.202000199 33169432
Cao Z, Wang X, Huang X, Mak HY. Are endoplasmic reticulum subdomains shaped by asymmetric distribution of phospholipids? Evidence from a C elegans model system. Bioessays. 2021;43(1):e2000199.33169432 10.1002/bies.202000199
36. Chung J Wu X Lambert TJ Lai ZW Walther TC Farese RV Jr LDAF1 and Seipin Form a Lipid Droplet Assembly Complex Dev Cell 2019 51 5 551 63.e7 10.1016/j.devcel.2019.10.006 31708432
Chung J, Wu X, Lambert TJ, Lai ZW, Walther TC, Farese RV Jr. LDAF1 and Seipin Form a Lipid Droplet Assembly Complex. Dev Cell. 2019;51(5):551-63.e7.31708432 10.1016/j.devcel.2019.10.006
37. Rao MJ Goodman JM Seipin: harvesting fat and keeping adipocytes healthy Trends Cell Biol 2021 31 11 912 923 10.1016/j.tcb.2021.06.003 34215489
Rao MJ, Goodman JM. Seipin: harvesting fat and keeping adipocytes healthy. Trends Cell Biol. 2021;31(11):912–23.34215489 10.1016/j.tcb.2021.06.003
38. Zoni V Khaddaj R Lukmantara I Shinoda W Yang H Schneiter R Seipin accumulates and traps diacylglycerols and triglycerides in its ring-like structure Proc Natl Acad Sci U S A 2021 118 10 10.1073/pnas.2017205118
Zoni V, Khaddaj R, Lukmantara I, Shinoda W, Yang H, Schneiter R, et al. Seipin accumulates and traps diacylglycerols and triglycerides in its ring-like structure. Proc Natl Acad Sci U S A. 2021;118:10.10.1073/pnas.2017205118
39. Talukder MM Sim MF O'Rahilly S Edwardson JM Rochford JJ Seipin oligomers can interact directly with AGPAT2 and lipin 1, physically scaffolding critical regulators of adipogenesis Mol Metab 2015 4 3 199 209 10.1016/j.molmet.2014.12.013 25737955
Talukder MM, Sim MF, O’Rahilly S, Edwardson JM, Rochford JJ. Seipin oligomers can interact directly with AGPAT2 and lipin 1, physically scaffolding critical regulators of adipogenesis. Mol Metab. 2015;4(3):199–209.25737955 10.1016/j.molmet.2014.12.013
40. Pagac M Cooper DE Qi Y Lukmantara IE Mak HY Wu Z SEIPIN regulates lipid droplet expansion and adipocyte development by modulating the activity of glycerol-3-phosphate acyltransferase Cell Rep 2016 17 6 1546 1559 10.1016/j.celrep.2016.10.037 27806294
Pagac M, Cooper DE, Qi Y, Lukmantara IE, Mak HY, Wu Z, et al. SEIPIN regulates lipid droplet expansion and adipocyte development by modulating the activity of glycerol-3-phosphate acyltransferase. Cell Rep. 2016;17(6):1546–59.27806294 10.1016/j.celrep.2016.10.037
41. Layerenza JP González P García de Bravo MM Polo MP Sisti MS Ves-Losada A Nuclear lipid droplets: a novel nuclear domain Biochim Biophys Acta 2013 1831 2 327 40 10.1016/j.bbalip.2012.10.005 23098923
Layerenza JP, González P, García de Bravo MM, Polo MP, Sisti MS, Ves-Losada A. Nuclear lipid droplets: a novel nuclear domain. Biochim Biophys Acta. 2013;1831(2):327–40.23098923 10.1016/j.bbalip.2012.10.005
42. Wang L Wang Y Liang Y Li J Liu Y Zhang J Specific accumulation of lipid droplets in hepatocyte nuclei of PFOA-exposed BALB/c mice Sci Rep 2013 3 2174 10.1038/srep02174 23846197
Wang L, Wang Y, Liang Y, Li J, Liu Y, Zhang J, et al. Specific accumulation of lipid droplets in hepatocyte nuclei of PFOA-exposed BALB/c mice. Sci Rep. 2013;3:2174.23846197 10.1038/srep02174
43. Wolinski H Hofbauer HF Hellauer K Cristobal-Sarramian A Kolb D Radulovic M Seipin is involved in the regulation of phosphatidic acid metabolism at a subdomain of the nuclear envelope in yeast Biochim Biophys Acta 2015 1851 11 1450 1464 10.1016/j.bbalip.2015.08.003 26275961
Wolinski H, Hofbauer HF, Hellauer K, Cristobal-Sarramian A, Kolb D, Radulovic M, et al. Seipin is involved in the regulation of phosphatidic acid metabolism at a subdomain of the nuclear envelope in yeast. Biochim Biophys Acta. 2015;1851(11):1450–64.26275961 10.1016/j.bbalip.2015.08.003
44. Barneda D Christian M Lipid droplet growth: regulation of a dynamic organelle Curr Opin Cell Biol 2017 47 9 15 10.1016/j.ceb.2017.02.002 28231490
Barneda D, Christian M. Lipid droplet growth: regulation of a dynamic organelle. Curr Opin Cell Biol. 2017;47:9–15.28231490 10.1016/j.ceb.2017.02.002
45. Haider A Wei YC Lim K Barbosa AD Liu CH Weber U PCYT1A regulates phosphatidylcholine homeostasis from the inner nuclear membrane in response to membrane stored curvature elastic stress Dev Cell 2018 45 4 481 95.e8 10.1016/j.devcel.2018.04.012 29754800
Haider A, Wei YC, Lim K, Barbosa AD, Liu CH, Weber U, et al. PCYT1A regulates phosphatidylcholine homeostasis from the inner nuclear membrane in response to membrane stored curvature elastic stress. Dev Cell. 2018;45(4):481-95.e8.29754800 10.1016/j.devcel.2018.04.012
46. Lee J Ridgway ND Phosphatidylcholine synthesis regulates triglyceride storage and chylomicron secretion by Caco2 cells J Lipid Res 2018 59 10 1940 1950 10.1194/jlr.M087635 30115754
Lee J, Ridgway ND. Phosphatidylcholine synthesis regulates triglyceride storage and chylomicron secretion by Caco2 cells. J Lipid Res. 2018;59(10):1940–50.30115754 10.1194/jlr.M087635
47. Gong J Sun Z Wu L Xu W Schieber N Xu D Fsp27 promotes lipid droplet growth by lipid exchange and transfer at lipid droplet contact sites J Cell Biol 2011 195 6 953 963 10.1083/jcb.201104142 22144693
Gong J, Sun Z, Wu L, Xu W, Schieber N, Xu D, et al. Fsp27 promotes lipid droplet growth by lipid exchange and transfer at lipid droplet contact sites. J Cell Biol. 2011;195(6):953–63.22144693 10.1083/jcb.201104142
48. Jambunathan S Yin J Khan W Tamori Y Puri V FSP27 promotes lipid droplet clustering and then fusion to regulate triglyceride accumulation PLoS ONE 2011 6 12 e28614 10.1371/journal.pone.0028614 22194867
Jambunathan S, Yin J, Khan W, Tamori Y, Puri V. FSP27 promotes lipid droplet clustering and then fusion to regulate triglyceride accumulation. PLoS ONE. 2011;6(12): e28614.22194867 10.1371/journal.pone.0028614
49. Xu W Wu L Yu M Chen FJ Arshad M Xia X Differential roles of cell death-inducing dna fragmentation factor-α-like effector (CIDE) proteins in promoting lipid droplet fusion and growth in subpopulations of hepatocytes J Biol Chem 2016 291 9 4282 4293 10.1074/jbc.M115.701094 26733203
Xu W, Wu L, Yu M, Chen FJ, Arshad M, Xia X, et al. Differential roles of cell death-inducing dna fragmentation factor-α-like effector (CIDE) proteins in promoting lipid droplet fusion and growth in subpopulations of hepatocytes. J Biol Chem. 2016;291(9):4282–93.26733203 10.1074/jbc.M115.701094
50. Wilfling F Wang H Haas JT Krahmer N Gould TJ Uchida A Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets Dev Cell 2013 24 4 384 399 10.1016/j.devcel.2013.01.013 23415954
Wilfling F, Wang H, Haas JT, Krahmer N, Gould TJ, Uchida A, et al. Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets. Dev Cell. 2013;24(4):384–99.23415954 10.1016/j.devcel.2013.01.013
51. Valdearcos M Esquinas E Meana C Gil-de-Gómez L Guijas C Balsinde J Subcellular localization and role of lipin-1 in human macrophages J Immunol 2011 186 10 6004 6013 10.4049/jimmunol.1003279 21478406
Valdearcos M, Esquinas E, Meana C, Gil-de-Gómez L, Guijas C, Balsinde J, et al. Subcellular localization and role of lipin-1 in human macrophages. J Immunol. 2011;186(10):6004–13.21478406 10.4049/jimmunol.1003279
52. Ohsaki Y Sołtysik K Fujimoto T The lipid droplet and the endoplasmic reticulum Adv Exp Med Biol 2017 997 111 120 10.1007/978-981-10-4567-7_8 28815525
Ohsaki Y, Sołtysik K, Fujimoto T. The lipid droplet and the endoplasmic reticulum. Adv Exp Med Biol. 2017;997:111–20.28815525 10.1007/978-981-10-4567-7_8
53. Huang W Gao F Zhang Y Chen T Xu C Lipid droplet-associated proteins in cardiomyopathy Ann Nutr Metab 2022 78 1 1 13 10.1159/000520122 34856540
Huang W, Gao F, Zhang Y, Chen T, Xu C. Lipid droplet-associated proteins in cardiomyopathy. Ann Nutr Metab. 2022;78(1):1–13.34856540 10.1159/000520122
54. Zadoorian A Du X Yang H Lipid droplet biogenesis and functions in health and disease Nat Rev Endocrinol 2023 19 8 443 459 10.1038/s41574-023-00845-0 37221402
Zadoorian A, Du X, Yang H. Lipid droplet biogenesis and functions in health and disease. Nat Rev Endocrinol. 2023;19(8):443–59.37221402 10.1038/s41574-023-00845-0
55. Prinz WA Bridging the gap: membrane contact sites in signaling, metabolism, and organelle dynamics J Cell Biol 2014 205 6 759 769 10.1083/jcb.201401126 24958771
Prinz WA. Bridging the gap: membrane contact sites in signaling, metabolism, and organelle dynamics. J Cell Biol. 2014;205(6):759–69.24958771 10.1083/jcb.201401126
56. Herms A Bosch M Reddy BJ Schieber NL Fajardo A Rupérez C AMPK activation promotes lipid droplet dispersion on detyrosinated microtubules to increase mitochondrial fatty acid oxidation Nat Commun 2015 6 7176 10.1038/ncomms8176 26013497
Herms A, Bosch M, Reddy BJ, Schieber NL, Fajardo A, Rupérez C, et al. AMPK activation promotes lipid droplet dispersion on detyrosinated microtubules to increase mitochondrial fatty acid oxidation. Nat Commun. 2015;6:7176.26013497 10.1038/ncomms8176
57. Granneman JG Moore HP Mottillo EP Zhu Z Zhou L Interactions of perilipin-5 (Plin5) with adipose triglyceride lipase J Biol Chem 2011 286 7 5126 5135 10.1074/jbc.M110.180711 21148142
Granneman JG, Moore HP, Mottillo EP, Zhu Z, Zhou L. Interactions of perilipin-5 (Plin5) with adipose triglyceride lipase. J Biol Chem. 2011;286(7):5126–35.21148142 10.1074/jbc.M110.180711
58. Boutant M Kulkarni SS Joffraud M Ratajczak J Valera-Alberni M Combe R Mfn2 is critical for brown adipose tissue thermogenic function Embo j 2017 36 11 1543 1558 10.15252/embj.201694914 28348166
Boutant M, Kulkarni SS, Joffraud M, Ratajczak J, Valera-Alberni M, Combe R, et al. Mfn2 is critical for brown adipose tissue thermogenic function. Embo j. 2017;36(11):1543–58.28348166 10.15252/embj.201694914
59. Fan H Tan Y Lipid droplet-mitochondria contacts in health and disease Int J Mol Sci 2024 25 13 10.3390/ijms25136878
Fan H, Tan Y. Lipid droplet-mitochondria contacts in health and disease. Int J Mol Sci. 2024;25:13.10.3390/ijms25136878
60. Dirkx R Vanhorebeek I Martens K Schad A Grabenbauer M Fahimi D Absence of peroxisomes in mouse hepatocytes causes mitochondrial and ER abnormalities Hepatology 2005 41 4 868 878 10.1002/hep.20628 15732085
Dirkx R, Vanhorebeek I, Martens K, Schad A, Grabenbauer M, Fahimi D, et al. Absence of peroxisomes in mouse hepatocytes causes mitochondrial and ER abnormalities. Hepatology. 2005;41(4):868–78.15732085 10.1002/hep.20628
61. Binns D Januszewski T Chen Y Hill J Markin VS Zhao Y An intimate collaboration between peroxisomes and lipid bodies J Cell Biol 2006 173 5 719 731 10.1083/jcb.200511125 16735577
Binns D, Januszewski T, Chen Y, Hill J, Markin VS, Zhao Y, et al. An intimate collaboration between peroxisomes and lipid bodies. J Cell Biol. 2006;173(5):719–31.16735577 10.1083/jcb.200511125
62. Young SG Zechner R Biochemistry and pathophysiology of intravascular and intracellular lipolysis Genes Dev 2013 27 5 459 484 10.1101/gad.209296.112 23475957
Young SG, Zechner R. Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev. 2013;27(5):459–84.23475957 10.1101/gad.209296.112
63. Zimmermann R Lass A Haemmerle G Zechner R Fate of fat: the role of adipose triglyceride lipase in lipolysis Biochim Biophys Acta 2009 1791 6 494 500 10.1016/j.bbalip.2008.10.005 19010445
Zimmermann R, Lass A, Haemmerle G, Zechner R. Fate of fat: the role of adipose triglyceride lipase in lipolysis. Biochim Biophys Acta. 2009;1791(6):494–500.19010445 10.1016/j.bbalip.2008.10.005
64. Grabner GF Zimmermann R Schicho R Taschler U Monoglyceride lipase as a drug target: at the crossroads of arachidonic acid metabolism and endocannabinoid signaling Pharmacol Ther 2017 175 35 46 10.1016/j.pharmthera.2017.02.033 28213089
Grabner GF, Zimmermann R, Schicho R, Taschler U. Monoglyceride lipase as a drug target: at the crossroads of arachidonic acid metabolism and endocannabinoid signaling. Pharmacol Ther. 2017;175:35–46.28213089 10.1016/j.pharmthera.2017.02.033
65. Zechner R Madeo F Kratky D Cytosolic lipolysis and lipophagy: two sides of the same coin Nat Rev Mol Cell Biol 2017 18 11 671 684 10.1038/nrm.2017.76 28852221
Zechner R, Madeo F, Kratky D. Cytosolic lipolysis and lipophagy: two sides of the same coin. Nat Rev Mol Cell Biol. 2017;18(11):671–84.28852221 10.1038/nrm.2017.76
66. Kimmel AR Sztalryd C The perilipins: major cytosolic lipid droplet-associated proteins and their roles in cellular lipid storage, mobilization, and systemic homeostasis Annu Rev Nutr 2016 36 471 509 10.1146/annurev-nutr-071813-105410 27431369
Kimmel AR, Sztalryd C. The perilipins: major cytosolic lipid droplet-associated proteins and their roles in cellular lipid storage, mobilization, and systemic homeostasis. Annu Rev Nutr. 2016;36:471–509.27431369 10.1146/annurev-nutr-071813-105410
67. Gutierrez MG Munafó DB Berón W Colombo MI Rab7 is required for the normal progression of the autophagic pathway in mammalian cells J Cell Sci 2004 117 Pt 13 2687 2697 10.1242/jcs.01114 15138286
Gutierrez MG, Munafó DB, Berón W, Colombo MI. Rab7 is required for the normal progression of the autophagic pathway in mammalian cells. J Cell Sci. 2004;117(Pt 13):2687–97.15138286 10.1242/jcs.01114
68. Balderhaar HJ Ungermann C CORVET and HOPS tethering complexes - coordinators of endosome and lysosome fusion J Cell Sci 2013 126 Pt 6 1307 1316 10.1242/jcs.107805 23645161
Balderhaar HJ, Ungermann C. CORVET and HOPS tethering complexes - coordinators of endosome and lysosome fusion. J Cell Sci. 2013;126(Pt 6):1307–16.23645161 10.1242/jcs.107805
69. Jiang JJ Zhang GF Zheng JY Sun JH Ding SB Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity Front Pharmacol 2022 13 876550 10.3389/fphar.2022.876550 35496312
Jiang JJ, Zhang GF, Zheng JY, Sun JH, Ding SB. Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity. Front Pharmacol. 2022;13: 876550.35496312 10.3389/fphar.2022.876550
70. Willebrords J Pereira IV Maes M Crespo Yanguas S Colle I Van Den Bossche B Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research Prog Lipid Res 2015 59 106 125 10.1016/j.plipres.2015.05.002 26073454
Willebrords J, Pereira IV, Maes M, Crespo Yanguas S, Colle I, Van Den Bossche B, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res. 2015;59:106–25.26073454 10.1016/j.plipres.2015.05.002
71. Mastoridou EM Goussia AC Kanavaros P Charchanti AV Involvement of lipophagy and chaperone-mediated autophagy in the pathogenesis of non-alcoholic fatty liver disease by regulation of lipid droplets Int J Mol Sci 2023 24 21 10.3390/ijms242115891
Mastoridou EM, Goussia AC, Kanavaros P, Charchanti AV. Involvement of lipophagy and chaperone-mediated autophagy in the pathogenesis of non-alcoholic fatty liver disease by regulation of lipid droplets. Int J Mol Sci. 2023;24:21.10.3390/ijms242115891
72. Straub BK Lipid droplet-associated proteins. Importance in steatosis, steatohepatitis and hepatocarcinogenesis Der Pathologe 2015 10.1007/s00292-015-0082-3 26400566
Straub BK. Lipid droplet-associated proteins. Importance in steatosis, steatohepatitis and hepatocarcinogenesis. Der Pathologe. 2015. 10.1007/s00292-015-0082-3.26400566 10.1007/s00292-015-0082-3
73. Sharma D Mandal P NAFLD: genetics and its clinical implications Clin Res Hepatol Gastroenterol 2022 46 9 102003 10.1016/j.clinre.2022.102003 35963605
Sharma D, Mandal P. NAFLD: genetics and its clinical implications. Clin Res Hepatol Gastroenterol. 2022;46(9): 102003.35963605 10.1016/j.clinre.2022.102003
74. Langhi C Arias N Rajamoorthi A Basta J Lee RG Baldán Á Therapeutic silencing of fat-specific protein 27 improves glycemic control in mouse models of obesity and insulin resistance J Lipid Res 2017 58 1 81 91 10.1194/jlr.M069799 27884961
Langhi C, Arias N, Rajamoorthi A, Basta J, Lee RG, Baldán Á. Therapeutic silencing of fat-specific protein 27 improves glycemic control in mouse models of obesity and insulin resistance. J Lipid Res. 2017;58(1):81–91.27884961 10.1194/jlr.M069799
75. McVicker BL Rasineni K Tuma DJ McNiven MA Casey CA Lipid droplet accumulation and impaired fat efflux in polarized hepatic cells: consequences of ethanol metabolism Int J Hepatol 2012 2012 978136 10.1155/2012/978136 22506128
McVicker BL, Rasineni K, Tuma DJ, McNiven MA, Casey CA. Lipid droplet accumulation and impaired fat efflux in polarized hepatic cells: consequences of ethanol metabolism. Int J Hepatol. 2012;2012: 978136.22506128 10.1155/2012/978136
76. Sans A Bonnafous S Rousseau D Patouraux S Canivet CM Leclere PS The differential expression of cide family members is associated with Nafld progression from steatosis to steatohepatitis Sci Rep 2019 9 1 7501 10.1038/s41598-019-43928-7 31097771
Sans A, Bonnafous S, Rousseau D, Patouraux S, Canivet CM, Leclere PS, et al. The differential expression of cide family members is associated with Nafld progression from steatosis to steatohepatitis. Sci Rep. 2019;9(1):7501.31097771 10.1038/s41598-019-43928-7
77. Listenberger LL Ostermeyer-Fay AG Goldberg EB Brown WJ Brown DA Adipocyte differentiation-related protein reduces the lipid droplet association of adipose triglyceride lipase and slows triacylglycerol turnover J Lipid Res 2007 48 12 2751 2761 10.1194/jlr.M700359-JLR200 17872589
Listenberger LL, Ostermeyer-Fay AG, Goldberg EB, Brown WJ, Brown DA. Adipocyte differentiation-related protein reduces the lipid droplet association of adipose triglyceride lipase and slows triacylglycerol turnover. J Lipid Res. 2007;48(12):2751–61.17872589 10.1194/jlr.M700359-JLR200
78. Ma YY Yin XC Qin ZZ Ke XF Mi Y Zheng PY Role of Plin5 deficiency in progression of non-alcoholic fatty liver disease induced by a high-fat diet in mice J Comp Pathol 2021 189 88 97 10.1016/j.jcpa.2021.10.002 34886991
Ma YY, Yin XC, Qin ZZ, Ke XF, Mi Y, Zheng PY, et al. Role of Plin5 deficiency in progression of non-alcoholic fatty liver disease induced by a high-fat diet in mice. J Comp Pathol. 2021;189:88–97.34886991 10.1016/j.jcpa.2021.10.002
79. Radner FP Streith IE Schoiswohl G Schweiger M Kumari M Eichmann TO Rechberger Growth retardation, impaired triacylglycerol catabolism, hepatic steatosis, and lethal skin barrier defect in mice lacking comparative gene identification-58 CGI-58 J Biol Chem 2010 285 10 10.1074/jbc.M109.081877
Radner FP, Streith IE, Schoiswohl G, Schweiger M, Kumari M, Eichmann TO, Rechberger, et al. Growth retardation, impaired triacylglycerol catabolism, hepatic steatosis, and lethal skin barrier defect in mice lacking comparative gene identification-58 CGI-58. J Biol Chem. 2010;285:10.10.1074/jbc.M109.081877
80. Wang Y Kory N BasuRay S Cohen JC Hobbs HH PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice Hepatology 2019 69 6 10.1002/hep.30583
Wang Y, Kory N, BasuRay S, Cohen JC, Hobbs HH. PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice. Hepatology. 2019;69:6.10.1002/hep.30583
81. Rasineni K McVicker BL Tuma DJ McNiven MA Casey CA Rab GTPases associate with isolated lipid droplets (LDs) and show altered content after ethanol administration: potential role in alcohol-impaired LD metabolism Alcohol Clin Exp Res 2014 38 2 327 335 10.1111/acer.12271 24117505
Rasineni K, McVicker BL, Tuma DJ, McNiven MA, Casey CA. Rab GTPases associate with isolated lipid droplets (LDs) and show altered content after ethanol administration: potential role in alcohol-impaired LD metabolism. Alcohol Clin Exp Res. 2014;38(2):327–35.24117505 10.1111/acer.12271
82. Ye J Li JZ Liu Y Li X Yang T Ma X Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B Cell Metab 2009 9 2 177 190 10.1016/j.cmet.2008.12.013 19187774
Ye J, Li JZ, Liu Y, Li X, Yang T, Ma X, et al. Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. Cell Metab. 2009;9(2):177–90.19187774 10.1016/j.cmet.2008.12.013
83. Dai C Kayton NS Shostak A Poffenberger G Cyphert HA Aramandla R Stress-impaired transcription factor expression and insulin secretion in transplanted human islets J Clin Invest 2016 126 5 1857 1870 10.1172/JCI83657 27064285
Dai C, Kayton NS, Shostak A, Poffenberger G, Cyphert HA, Aramandla R, et al. Stress-impaired transcription factor expression and insulin secretion in transplanted human islets. J Clin Invest. 2016;126(5):1857–70.27064285 10.1172/JCI83657
84. Li Q Zhao Y Guo H Li Q Yan C Li Y Impaired lipophagy induced-microglial lipid droplets accumulation contributes to the buildup of TREM1 in diabetes-associated cognitive impairment Autophagy 2023 19 10 2639 2656 10.1080/15548627.2023.2213984 37204119
Li Q, Zhao Y, Guo H, Li Q, Yan C, Li Y, et al. Impaired lipophagy induced-microglial lipid droplets accumulation contributes to the buildup of TREM1 in diabetes-associated cognitive impairment. Autophagy. 2023;19(10):2639–56.37204119 10.1080/15548627.2023.2213984
85. Yang M Luo S Yang J Chen W He L Liu D Lipid droplet - mitochondria coupling: A novel lipid metabolism regulatory hub in diabetic nephropathy Front Endocrinol (Lausanne) 2022 13 1017387 10.3389/fendo.2022.1017387 36387849
Yang M, Luo S, Yang J, Chen W, He L, Liu D, et al. Lipid droplet - mitochondria coupling: A novel lipid metabolism regulatory hub in diabetic nephropathy. Front Endocrinol (Lausanne). 2022;13:1017387.36387849 10.3389/fendo.2022.1017387
86. Schelling JR The contribution of lipotoxicity to diabetic kidney disease Cells 2022 11 20 10.3390/cells11203236
Schelling JR. The contribution of lipotoxicity to diabetic kidney disease. Cells. 2022;11:20.10.3390/cells11203236
87. Yoshioka K Hirakawa Y Kurano M Ube Y Ono Y Kojima K Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease Kidney Int 2022 101 3 510 526 10.1016/j.kint.2021.10.039 34856312
Yoshioka K, Hirakawa Y, Kurano M, Ube Y, Ono Y, Kojima K, et al. Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease. Kidney Int. 2022;101(3):510–26.34856312 10.1016/j.kint.2021.10.039
88. Tang T Abbott MJ Ahmadian M Lopes AB Wang Y Sul HS Desnutrin/ATGL activates PPARδ to promote mitochondrial function for insulin secretion in islet β cells Cell Metab 2013 18 6 883 895 10.1016/j.cmet.2013.10.012 24268737
Tang T, Abbott MJ, Ahmadian M, Lopes AB, Wang Y, Sul HS. Desnutrin/ATGL activates PPARδ to promote mitochondrial function for insulin secretion in islet β cells. Cell Metab. 2013;18(6):883–95.24268737 10.1016/j.cmet.2013.10.012
89. Zhao S Mugabo Y Iglesias J Xie L Delghingaro-Augusto V Lussier R α/β-Hydrolase domain-6-accessible monoacylglycerol controls glucose-stimulated insulin secretion Cell Metab 2014 19 6 993 1007 10.1016/j.cmet.2014.04.003 24814481
Zhao S, Mugabo Y, Iglesias J, Xie L, Delghingaro-Augusto V, Lussier R, et al. α/β-Hydrolase domain-6-accessible monoacylglycerol controls glucose-stimulated insulin secretion. Cell Metab. 2014;19(6):993–1007.24814481 10.1016/j.cmet.2014.04.003
90. Liu S Promes JA Harata M Mishra A Stephens SB Taylor EB Adipose triglyceride lipase is a key lipase for the mobilization of lipid droplets in human β-cells and critical for the maintenance of syntaxin 1a levels in β-cells Diabetes 2020 69 6 1178 1192 10.2337/db19-0951 32312867
Liu S, Promes JA, Harata M, Mishra A, Stephens SB, Taylor EB, et al. Adipose triglyceride lipase is a key lipase for the mobilization of lipid droplets in human β-cells and critical for the maintenance of syntaxin 1a levels in β-cells. Diabetes. 2020;69(6):1178–92.32312867 10.2337/db19-0951
91. Ma H Guo X Cui S Wu Y Zhang Y Shen X Dephosphorylation of AMP-activated protein kinase exacerbates ischemia/reperfusion-induced acute kidney injury via mitochondrial dysfunction Kidney Int 2022 101 2 315 330 10.1016/j.kint.2021.10.028 34774556
Ma H, Guo X, Cui S, Wu Y, Zhang Y, Shen X, et al. Dephosphorylation of AMP-activated protein kinase exacerbates ischemia/reperfusion-induced acute kidney injury via mitochondrial dysfunction. Kidney Int. 2022;101(2):315–30.34774556 10.1016/j.kint.2021.10.028
92. den Braanker DJW Maas RJH van Mierlo G Parr NMJ Bakker-van Bebber M Deegens JKJ Primary focal segmental glomerulosclerosis plasmas increase lipid droplet formation and perilipin-2 expression in human podocytes Int J Mol Sci 2022 24 1 36613445
den Braanker DJW, Maas RJH, van Mierlo G, Parr NMJ, Bakker-van Bebber M, Deegens JKJ, et al. Primary focal segmental glomerulosclerosis plasmas increase lipid droplet formation and perilipin-2 expression in human podocytes. Int J Mol Sci. 2022;24:1.36613445
93. Li H Dixon EE Wu H Humphreys BD Comprehensive single-cell transcriptional profiling defines shared and unique epithelial injury responses during kidney fibrosis Cell Metab 2022 34 12 1977 98.e9 10.1016/j.cmet.2022.09.026 36265491
Li H, Dixon EE, Wu H, Humphreys BD. Comprehensive single-cell transcriptional profiling defines shared and unique epithelial injury responses during kidney fibrosis. Cell Metab. 2022;34(12):1977-98.e9.36265491 10.1016/j.cmet.2022.09.026
94. Chen Y Dai Y Song K Huang Y Zhang L Zhang C Pre-emptive pharmacological inhibition of fatty acid-binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism Cell Death Dis 2021 12 6 572 10.1038/s41419-021-03850-1 34083513
Chen Y, Dai Y, Song K, Huang Y, Zhang L, Zhang C, et al. Pre-emptive pharmacological inhibition of fatty acid-binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism. Cell Death Dis. 2021;12(6):572.34083513 10.1038/s41419-021-03850-1
95. Vijayan A Tackling AKI: prevention, timing of dialysis and follow-up Nat Rev Nephrol 2021 17 2 87 88 10.1038/s41581-020-00390-3 33335277
Vijayan A. Tackling AKI: prevention, timing of dialysis and follow-up. Nat Rev Nephrol. 2021;17(2):87–8.33335277 10.1038/s41581-020-00390-3
96. Yuan Y Sun H Sun Z Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN) Lipids Health Dis 2017 16 1 126 10.1186/s12944-017-0522-6 28659153
Yuan Y, Sun H, Sun Z. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN). Lipids Health Dis. 2017;16(1):126.28659153 10.1186/s12944-017-0522-6
97. Yu M Wang H Zhao J Yuan Y Wang C Li J Expression of CIDE proteins in clear cell renal cell carcinoma and their prognostic significance Mol Cell Biochem 2013 378 1–2 145 151 10.1007/s11010-013-1605-y 23475172
Yu M, Wang H, Zhao J, Yuan Y, Wang C, Li J, et al. Expression of CIDE proteins in clear cell renal cell carcinoma and their prognostic significance. Mol Cell Biochem. 2013;378(1–2):145–51.23475172 10.1007/s11010-013-1605-y
98. Chen Z Shrestha R Yang X Wu X Jia J Chiba H Oxidative stress and lipid dysregulation in lipid droplets: a connection to chronic kidney disease revealed in human kidney cells Antioxidants (Basel) 2022 11 7
Chen Z, Shrestha R, Yang X, Wu X, Jia J, Chiba H, et al. Oxidative stress and lipid dysregulation in lipid droplets: a connection to chronic kidney disease revealed in human kidney cells. Antioxidants (Basel). 2022;11:7.
99. Mitrofanova A Merscher S Fornoni A Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease Nat Rev Nephrol 2023 19 10 629 645 10.1038/s41581-023-00741-w 37500941
Mitrofanova A, Merscher S, Fornoni A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nat Rev Nephrol. 2023;19(10):629–45.37500941 10.1038/s41581-023-00741-w
100. Chen FL Yang ZH Wang XC Liu Y Yang YH Li LX Adipophilin affects the expression of TNF-alpha, MCP-1, and IL-6 in THP-1 macrophages Mol Cell Biochem 2010 337 1–2 193 199 10.1007/s11010-009-0299-7 19851831
Chen FL, Yang ZH, Wang XC, Liu Y, Yang YH, Li LX, et al. Adipophilin affects the expression of TNF-alpha, MCP-1, and IL-6 in THP-1 macrophages. Mol Cell Biochem. 2010;337(1–2):193–9.19851831 10.1007/s11010-009-0299-7
101. Nuotio K Isoviita PM Saksi J Ijäs P Pitkäniemi J Sonninen R Adipophilin expression is increased in symptomatic carotid atherosclerosis: correlation with red blood cells and cholesterol crystals Stroke 2007 38 6 1791 1798 10.1161/STROKEAHA.106.478867 17446422
Nuotio K, Isoviita PM, Saksi J, Ijäs P, Pitkäniemi J, Sonninen R, et al. Adipophilin expression is increased in symptomatic carotid atherosclerosis: correlation with red blood cells and cholesterol crystals. Stroke. 2007;38(6):1791–8.17446422 10.1161/STROKEAHA.106.478867
102. Larigauderie G Furman C Jaye M Lasselin C Copin C Fruchart JC Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis Arterioscler Thromb Vasc Biol 2004 24 3 504 510 10.1161/01.ATV.0000115638.27381.97 14707038
Larigauderie G, Furman C, Jaye M, Lasselin C, Copin C, Fruchart JC, et al. Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol. 2004;24(3):504–10.14707038 10.1161/01.ATV.0000115638.27381.97
103. Li JZ Lei Y Wang Y Zhang Y Ye J Xia X Control of cholesterol biosynthesis, uptake and storage in hepatocytes by Cideb Biochim Biophys Acta 2010 1801 5 577 586 10.1016/j.bbalip.2010.01.012 20123130
Li JZ, Lei Y, Wang Y, Zhang Y, Ye J, Xia X, et al. Control of cholesterol biosynthesis, uptake and storage in hepatocytes by Cideb. Biochim Biophys Acta. 2010;1801(5):577–86.20123130 10.1016/j.bbalip.2010.01.012
104. Goo YH Son SH Kreienberg PB Paul A Novel lipid droplet-associated serine hydrolase regulates macrophage cholesterol mobilization Arterioscler Thromb Vasc Biol 2014 34 2 386 396 10.1161/ATVBAHA.113.302448 24357060
Goo YH, Son SH, Kreienberg PB, Paul A. Novel lipid droplet-associated serine hydrolase regulates macrophage cholesterol mobilization. Arterioscler Thromb Vasc Biol. 2014;34(2):386–96.24357060 10.1161/ATVBAHA.113.302448
105. Ethem İ Hacıoğlu C Effects of perilipin-5 on lipid metabolism and high-sensitivity cardiac troponin I Rev Assoc Med Bras 2022 68 8 1011 6 10.1590/1806-9282.20211377 36134829
Ethem İ, Hacıoğlu C. Effects of perilipin-5 on lipid metabolism and high-sensitivity cardiac troponin I. Rev Assoc Med Bras. 2022;68(8):1011–6.36134829 10.1590/1806-9282.20211377
106. Zhao YB Zhao J Zhang LJ Shan RG Sun ZZ Wang K MicroRNA-370 protects against myocardial ischemia/reperfusion injury in mice following sevoflurane anesthetic preconditioning through PLIN5-dependent PPAR signaling pathway Biomed Pharmacother 2019 113 108697 10.1016/j.biopha.2019.108697 30856533
Zhao YB, Zhao J, Zhang LJ, Shan RG, Sun ZZ, Wang K, et al. MicroRNA-370 protects against myocardial ischemia/reperfusion injury in mice following sevoflurane anesthetic preconditioning through PLIN5-dependent PPAR signaling pathway. Biomed Pharmacother. 2019;113: 108697.30856533 10.1016/j.biopha.2019.108697
107. Nakamura M Sadoshima J Cardiomyopathy in obesity, insulin resistance and diabetes J Physiol 2020 598 14 2977 2993 10.1113/JP276747 30869158
Nakamura M, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol. 2020;598(14):2977–93.30869158 10.1113/JP276747
108. Currie E Schulze A Zechner R Walther TC Farese RV Jr Cellular fatty acid metabolism and cancer Cell Metab 2013 18 2 153 161 10.1016/j.cmet.2013.05.017 23791484
Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153–61.23791484 10.1016/j.cmet.2013.05.017
109. Weinberg JM Lipotoxicity Kidney Int 2006 70 9 1560 1566 10.1038/sj.ki.5001834 16955100
Weinberg JM. Lipotoxicity. Kidney Int. 2006;70(9):1560–6.16955100 10.1038/sj.ki.5001834
110. Chen JR Ding CF Chen YH Hu WD Yu CK Peng CH ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway Cancer Lett 2021 502 154 165 10.1016/j.canlet.2020.12.019 33340617
Chen JR, Ding CF, Chen YH, Hu WD, Yu CK, Peng CH, et al. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway. Cancer Lett. 2021;502:154–65.33340617 10.1016/j.canlet.2020.12.019
111. Quan Y Dai J Zhou S Zhao L Jin L Long Y HIF2α-induced upregulation of RNASET2 promotes triglyceride synthesis and enhances cell migration in clear cell renal cell carcinoma FEBS Open Bio 2023 10.1002/2211-5463.13570 36728187
Quan Y, Dai J, Zhou S, Zhao L, Jin L, Long Y, et al. HIF2α-induced upregulation of RNASET2 promotes triglyceride synthesis and enhances cell migration in clear cell renal cell carcinoma. FEBS Open Bio. 2023. 10.1002/2211-5463.13570.36728187 10.1002/2211-5463.13570
112. Klasson TD LaGory EL Zhao H Huynh SK Papandreou I Moon EJ ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma Cancer Metab 2022 10 1 14 10.1186/s40170-022-00290-z 36192773
Klasson TD, LaGory EL, Zhao H, Huynh SK, Papandreou I, Moon EJ, et al. ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma. Cancer Metab. 2022;10(1):14.36192773 10.1186/s40170-022-00290-z
113. Wang K Ruan H Song Z Cao Q Bao L Liu D PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma Urol Oncol 2018 36 7 10.1016/j.urolonc.2018.04.006
Wang K, Ruan H, Song Z, Cao Q, Bao L, Liu D, et al. PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma. Urol Oncol. 2018;36:7.10.1016/j.urolonc.2018.04.006
114. Moldavski O Amen T Levin-Zaidman S Eisenstein M Rogachev I Brandis A Lipid droplets are essential for efficient clearance of cytosolic inclusion bodies Dev Cell 2015 33 5 603 610 10.1016/j.devcel.2015.04.015 26004510
Moldavski O, Amen T, Levin-Zaidman S, Eisenstein M, Rogachev I, Brandis A, et al. Lipid droplets are essential for efficient clearance of cytosolic inclusion bodies. Dev Cell. 2015;33(5):603–10.26004510 10.1016/j.devcel.2015.04.015
115. Luo W Wang H Ren L Lu Z Zheng Q Ding L Adding fuel to the fire: the lipid droplet and its associated proteins in cancer progression Int J Biol Sci 2022 18 16 6020 6034 10.7150/ijbs.74902 36439875
Luo W, Wang H, Ren L, Lu Z, Zheng Q, Ding L, et al. Adding fuel to the fire: the lipid droplet and its associated proteins in cancer progression. Int J Biol Sci. 2022;18(16):6020–34.36439875 10.7150/ijbs.74902
116. Morrissey JJ Mobley J Figenshau RS Vetter J Bhayani S Kharasch ED Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer Mayo Clin Proc 2015 90 1 35 42 10.1016/j.mayocp.2014.10.005 25572193
Morrissey JJ, Mobley J, Figenshau RS, Vetter J, Bhayani S, Kharasch ED. Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer. Mayo Clin Proc. 2015;90(1):35–42.25572193 10.1016/j.mayocp.2014.10.005
117. Lucenay KS Doostan I Karakas C Bui T Ding Z Mills GB Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells Cancer Res 2016 76 8 2406 2418 10.1158/0008-5472.CAN-15-1646 26928812
Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, et al. Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Res. 2016;76(8):2406–18.26928812 10.1158/0008-5472.CAN-15-1646
118. Matsubara J Honda K Ono M Sekine S Tanaka Y Kobayashi M Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray Cancer Epidemiol Biomarkers Prev 2011 20 10 2195 2203 10.1158/1055-9965.EPI-11-0400 21828233
Matsubara J, Honda K, Ono M, Sekine S, Tanaka Y, Kobayashi M, et al. Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2195–203.21828233 10.1158/1055-9965.EPI-11-0400
119. Zhang X Su L Sun K Expression status and prognostic value of the perilipin family of genes in breast cancer Am J Transl Res 2021 13 5 4450 4463 34150026
Zhang X, Su L, Sun K. Expression status and prognostic value of the perilipin family of genes in breast cancer. Am J Transl Res. 2021;13(5):4450–63.34150026
120. Zammouri J Vatier C Capel E Auclair M Storey-London C Bismuth E Molecular and cellular bases of lipodystrophy syndromes Front Endocrinol (Lausanne) 2021 12 803189 10.3389/fendo.2021.803189 35046902
Zammouri J, Vatier C, Capel E, Auclair M, Storey-London C, Bismuth E, et al. Molecular and cellular bases of lipodystrophy syndromes. Front Endocrinol (Lausanne). 2021;12: 803189.35046902 10.3389/fendo.2021.803189
121. Xu S Zhang X Liu P Lipid droplet proteins and metabolic diseases Biochim Biophys Acta Mol Basis Dis 2018 10.1016/j.bbadis.2017.07.019 30562559
Xu S, Zhang X, Liu P. Lipid droplet proteins and metabolic diseases. Biochim Biophys Acta Mol Basis Dis. 2018. 10.1016/j.bbadis.2017.07.019.30562559 10.1016/j.bbadis.2017.07.019
122. Moriya K Yotsuyanagi H Shintani Y Fujie H Ishibashi K Matsuura Y Hepatitis C virus core protein induces hepatic steatosis in transgenic mice J Gen Virol 1997 78 Pt 7 1527 1531 10.1099/0022-1317-78-7-1527 9225025
Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78(Pt 7):1527–31.9225025 10.1099/0022-1317-78-7-1527
123. Salloum S Wang H Ferguson C Parton RG Tai AW Rab18 binds to hepatitis C virus NS5A and promotes interaction between sites of viral replication and lipid droplets PLoS Pathog 2013 9 8 e1003513 10.1371/journal.ppat.1003513 23935497
Salloum S, Wang H, Ferguson C, Parton RG, Tai AW. Rab18 binds to hepatitis C virus NS5A and promotes interaction between sites of viral replication and lipid droplets. PLoS Pathog. 2013;9(8): e1003513.23935497 10.1371/journal.ppat.1003513
124. Ferguson D Zhang J Davis MA Helsley RN Vedin LL Lee RG The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis J Lipid Res 2017 58 2 420 432 10.1194/jlr.M073734 27941027
Ferguson D, Zhang J, Davis MA, Helsley RN, Vedin LL, Lee RG, et al. The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis. J Lipid Res. 2017;58(2):420–32.27941027 10.1194/jlr.M073734
125. Hinson ER Cresswell P The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic alpha-helix Proc Natl Acad Sci U S A 2009 106 48 20452 20457 10.1073/pnas.0911679106 19920176
Hinson ER, Cresswell P. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic alpha-helix. Proc Natl Acad Sci U S A. 2009;106(48):20452–7.19920176 10.1073/pnas.0911679106
126. Kloska A Węsierska M Malinowska M Gabig-Cimińska M Jakóbkiewicz-Banecka J Lipophagy and lipolysis status in lipid storage and lipid metabolism diseases Int J Mol Sci 2020 21 17 10.3390/ijms21176113
Kloska A, Węsierska M, Malinowska M, Gabig-Cimińska M, Jakóbkiewicz-Banecka J. Lipophagy and lipolysis status in lipid storage and lipid metabolism diseases. Int J Mol Sci. 2020;21:17.10.3390/ijms21176113
127. Pol A Gross SP Parton RG Review: biogenesis of the multifunctional lipid droplet: lipids, proteins, and sites J Cell Biol 2014 204 5 635 646 10.1083/jcb.201311051 24590170
Pol A, Gross SP, Parton RG. Review: biogenesis of the multifunctional lipid droplet: lipids, proteins, and sites. J Cell Biol. 2014;204(5):635–46.24590170 10.1083/jcb.201311051
128. Yao J Wei W Wen J Cao Y Li H The efficacy and mechanism of berberine in improving aging-related cognitive dysfunction: A study based on network pharmacology Front Neurosci 2023 17 1093180 10.3389/fnins.2023.1093180 36743801
Yao J, Wei W, Wen J, Cao Y, Li H. The efficacy and mechanism of berberine in improving aging-related cognitive dysfunction: A study based on network pharmacology. Front Neurosci. 2023;17:1093180.36743801 10.3389/fnins.2023.1093180
129. Zhu X Bian H Wang L Sun X Xu X Yan H Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway Free Radic Biol Med 2019 141 192 204 10.1016/j.freeradbiomed.2019.06.019 31226399
Zhu X, Bian H, Wang L, Sun X, Xu X, Yan H, et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med. 2019;141:192–204.31226399 10.1016/j.freeradbiomed.2019.06.019
130. Yu M Alimujiang M Hu L Liu F Bao Y Yin J Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver Int J Biol Sci 2021 17 7 1693 1707 10.7150/ijbs.54604 33994854
Yu M, Alimujiang M, Hu L, Liu F, Bao Y, Yin J. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. Int J Biol Sci. 2021;17(7):1693–707.33994854 10.7150/ijbs.54604
131. Wang L Xu BY Sagada G Ng WK Chen K Zhang JZ Dietary berberine regulates lipid metabolism in muscle and liver of black sea bream (Acanthopagrus schlegelii) fed normal or high-lipid diets Br J Nutr 2021 125 5 481 493 10.1017/S0007114520003025 32718379
Wang L, Xu BY, Sagada G, Ng WK, Chen K, Zhang JZ, et al. Dietary berberine regulates lipid metabolism in muscle and liver of black sea bream (Acanthopagrus schlegelii) fed normal or high-lipid diets. Br J Nutr. 2021;125(5):481–93.32718379 10.1017/S0007114520003025
132. Dai J Huang X Zhang C Luo X Cao S Wang J Berberine regulates lipid metabolism via miR-192 in porcine oocytes matured in vitro Vet Med Sci 2021 7 3 950 959 10.1002/vms3.393 33818910
Dai J, Huang X, Zhang C, Luo X, Cao S, Wang J, et al. Berberine regulates lipid metabolism via miR-192 in porcine oocytes matured in vitro. Vet Med Sci. 2021;7(3):950–9.33818910 10.1002/vms3.393
133. Liu YX Fang XJ Li Y Bing L Li Y Fang J Berberine suppresses the migration and invasion of colon cancer cells by inhibition of lipogenesis through modulation of promyelocytic leukemia zinc finger-mediated sterol-regulatory element binding proteins cleavage-activating protein ubiquitination J Pharm Pharmacol 2022 74 9 1353 1363 10.1093/jpp/rgac026 35641094
Liu YX, Fang XJ, Li Y, Bing L, Li Y, Fang J, et al. Berberine suppresses the migration and invasion of colon cancer cells by inhibition of lipogenesis through modulation of promyelocytic leukemia zinc finger-mediated sterol-regulatory element binding proteins cleavage-activating protein ubiquitination. J Pharm Pharmacol. 2022;74(9):1353–63.35641094 10.1093/jpp/rgac026
134. Jyotshna KP Mangiferin SK A review of sources and interventions for biological activities Biofactors 2016 42 5 504 14 10.1002/biof.1308 27658353
Jyotshna KP, Mangiferin SK. A review of sources and interventions for biological activities. Biofactors. 2016;42(5):504–14.27658353 10.1002/biof.1308
135. Na L Zhang Q Jiang S Du S Zhang W Li Y Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial Sci Rep 2015 5 10344 10.1038/srep10344 25989216
Na L, Zhang Q, Jiang S, Du S, Zhang W, Li Y, et al. Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial. Sci Rep. 2015;5:10344.25989216 10.1038/srep10344
136. Fomenko EV Chi Y Mangiferin modulation of metabolism and metabolic syndrome BioFactors 2016 42 5 492 503 10.1002/biof.1309 27534809
Fomenko EV, Chi Y. Mangiferin modulation of metabolism and metabolic syndrome. BioFactors. 2016;42(5):492–503.27534809 10.1002/biof.1309
137. Sim MO Lee HJ Jeong DE Jang JH Jung HK Cho HW 6'-O-acetyl mangiferin from Iris rossii Baker inhibits lipid accumulation partly via AMPK activation in adipogenesis Chem Biol Interact 2019 311 108755 10.1016/j.cbi.2019.108755 31319077
Sim MO, Lee HJ, Jeong DE, Jang JH, Jung HK, Cho HW. 6’-O-acetyl mangiferin from Iris rossii Baker inhibits lipid accumulation partly via AMPK activation in adipogenesis. Chem Biol Interact. 2019;311: 108755.31319077 10.1016/j.cbi.2019.108755
138. Niu Y Li S Na L Feng R Liu L Li Y Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK PLoS ONE 2012 7 1 e30782 10.1371/journal.pone.0030782 22292039
Niu Y, Li S, Na L, Feng R, Liu L, Li Y, et al. Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. PLoS ONE. 2012;7(1): e30782.22292039 10.1371/journal.pone.0030782
139. Tehrani SS Goodarzi G Panahi G Zamani-Garmsiri F Meshkani R The combination of metformin with morin alleviates hepatic steatosis via modulating hepatic lipid metabolism, hepatic inflammation, brown adipose tissue thermogenesis, and white adipose tissue browning in high-fat diet-fed mice Life Sci 2023 323 121706 10.1016/j.lfs.2023.121706 37075944
Tehrani SS, Goodarzi G, Panahi G, Zamani-Garmsiri F, Meshkani R. The combination of metformin with morin alleviates hepatic steatosis via modulating hepatic lipid metabolism, hepatic inflammation, brown adipose tissue thermogenesis, and white adipose tissue browning in high-fat diet-fed mice. Life Sci. 2023;323: 121706.37075944 10.1016/j.lfs.2023.121706
140. Zhang Q Kong X Yuan H Guan H Li Y Niu Y Mangiferin improved palmitate-induced-insulin resistance by promoting free fatty acid metabolism in HepG2 and C2C12 Cells via PPARα: mangiferin improved insulin resistance J Diabetes Res 2019 2019 2052675 10.1155/2019/2052675 30809553
Zhang Q, Kong X, Yuan H, Guan H, Li Y, Niu Y. Mangiferin improved palmitate-induced-insulin resistance by promoting free fatty acid metabolism in HepG2 and C2C12 Cells via PPARα: mangiferin improved insulin resistance. J Diabetes Res. 2019;2019:2052675.30809553 10.1155/2019/2052675
141. Guo F Huang C Liao X Wang Y He Y Feng R Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters Mol Nutr Food Res 2011 55 12 1809 1818 10.1002/mnfr.201100392 22038976
Guo F, Huang C, Liao X, Wang Y, He Y, Feng R, et al. Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol Nutr Food Res. 2011;55(12):1809–18.22038976 10.1002/mnfr.201100392
142. Ren K Li H Zhou HF Liang Y Tong M Chen L Mangiferin promotes macrophage cholesterol efflux and protects against atherosclerosis by augmenting the expression of ABCA1 and ABCG1 Aging (Albany NY) 2019 11 23 10992 11009 10.18632/aging.102498 31790366
Ren K, Li H, Zhou HF, Liang Y, Tong M, Chen L, et al. Mangiferin promotes macrophage cholesterol efflux and protects against atherosclerosis by augmenting the expression of ABCA1 and ABCG1. Aging (Albany NY). 2019;11(23):10992–1009.31790366 10.18632/aging.102498
143. Rodriguez-Gonzalez JC Hernández-Balmaseda I Declerck K Pérez-Novo C Logie E Theys C Antiproliferative, antiangiogenic, and antimetastatic therapy response by mangiferin in a syngeneic immunocompetent colorectal cancer mouse model involves changes in mitochondrial energy metabolism Front Pharmacol 2021 12 670167 10.3389/fphar.2021.670167 34924998
Rodriguez-Gonzalez JC, Hernández-Balmaseda I, Declerck K, Pérez-Novo C, Logie E, Theys C, et al. Antiproliferative, antiangiogenic, and antimetastatic therapy response by mangiferin in a syngeneic immunocompetent colorectal cancer mouse model involves changes in mitochondrial energy metabolism. Front Pharmacol. 2021;12: 670167.34924998 10.3389/fphar.2021.670167
144. Li J Liu M Yu H Wang W Han L Chen Q Mangiferin improves hepatic lipid metabolism mainly through its metabolite-norathyriol by modulating SIRT-1/AMPK/SREBP-1c signaling Front Pharmacol 2018 9 201 10.3389/fphar.2018.00201 29563875
Li J, Liu M, Yu H, Wang W, Han L, Chen Q, et al. Mangiferin improves hepatic lipid metabolism mainly through its metabolite-norathyriol by modulating SIRT-1/AMPK/SREBP-1c signaling. Front Pharmacol. 2018;9:201.29563875 10.3389/fphar.2018.00201
145. Yu S Zhang W Zhang L Wu D Sun P Huang C MYB24 negatively regulates the biosynthesis of lignin and capsaicin by affecting the expression of key genes in the phenylpropanoid metabolism pathway in capsicum Chinense Molecules 2023 28 6
Yu S, Zhang W, Zhang L, Wu D, Sun P, Huang C, et al. MYB24 negatively regulates the biosynthesis of lignin and capsaicin by affecting the expression of key genes in the phenylpropanoid metabolism pathway in capsicum Chinense. Molecules. 2023;28:6.
146. Hochkogler CM Lieder B Schachner D Heiss E Schröter A Hans J Capsaicin and nonivamide similarly modulate outcome measures of mitochondrial energy metabolism in HepG2 and 3T3-L1 cells Food Funct 2018 9 2 1123 1132 10.1039/C7FO01626C 29362767
Hochkogler CM, Lieder B, Schachner D, Heiss E, Schröter A, Hans J, et al. Capsaicin and nonivamide similarly modulate outcome measures of mitochondrial energy metabolism in HepG2 and 3T3-L1 cells. Food Funct. 2018;9(2):1123–32.29362767 10.1039/C7FO01626C
147. Baek J Lee J Kim K Kim T Kim D Kim C Inhibitory effects of Capsicum annuum L water extracts on lipoprotein lipase activity in 3T3-L1 cells Nutr Res Pract 2013 7 2 96 102 10.4162/nrp.2013.7.2.96 23610601
Baek J, Lee J, Kim K, Kim T, Kim D, Kim C, et al. Inhibitory effects of Capsicum annuum L water extracts on lipoprotein lipase activity in 3T3-L1 cells. Nutr Res Pract. 2013;7(2):96–102.23610601 10.4162/nrp.2013.7.2.96
148. Hwang JT Park IJ Shin JI Lee YK Lee SK Baik HW Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase Biochem Biophys Res Commun 2005 338 2 694 699 10.1016/j.bbrc.2005.09.195 16236247
Hwang JT, Park IJ, Shin JI, Lee YK, Lee SK, Baik HW, et al. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun. 2005;338(2):694–9.16236247 10.1016/j.bbrc.2005.09.195
149. Lee MS Kim CT Kim IH Kim Y Effects of capsaicin on lipid catabolism in 3T3-L1 adipocytes Phytother Res 2011 25 6 935 939 10.1002/ptr.3339 21626599
Lee MS, Kim CT, Kim IH, Kim Y. Effects of capsaicin on lipid catabolism in 3T3-L1 adipocytes. Phytother Res. 2011;25(6):935–9.21626599 10.1002/ptr.3339
150. Chen J Li L Li Y Liang X Sun Q Yu H Activation of TRPV1 channel by dietary capsaicin improves visceral fat remodeling through connexin43-mediated Ca2+ influx Cardiovasc Diabetol 2015 14 22 10.1186/s12933-015-0183-6 25849380
Chen J, Li L, Li Y, Liang X, Sun Q, Yu H, et al. Activation of TRPV1 channel by dietary capsaicin improves visceral fat remodeling through connexin43-mediated Ca2+ influx. Cardiovasc Diabetol. 2015;14:22.25849380 10.1186/s12933-015-0183-6
151. Bort A Sánchez BG Mateos-Gómez PA Díaz-Laviada I Rodríguez-Henche N Capsaicin targets lipogenesis in HepG2 cells through AMPK activation, AKT inhibition and PPARs regulation Int J Mol Sci 2019 20 7 10.3390/ijms20071660
Bort A, Sánchez BG, Mateos-Gómez PA, Díaz-Laviada I, Rodríguez-Henche N. Capsaicin targets lipogenesis in HepG2 cells through AMPK activation, AKT inhibition and PPARs regulation. Int J Mol Sci. 2019;20:7.10.3390/ijms20071660
152. Li Q Li L Wang F Chen J Zhao Y Wang P Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor δ activation Pflugers Arch 2013 465 9 1303 1316 10.1007/s00424-013-1274-4 23605066
Li Q, Li L, Wang F, Chen J, Zhao Y, Wang P, et al. Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor δ activation. Pflugers Arch. 2013;465(9):1303–16.23605066 10.1007/s00424-013-1274-4
153. Jeong JY Suresh S Park MN Jang M Park S Gobianand K Effects of capsaicin on adipogenic differentiation in bovine bone marrow mesenchymal stem cell Asian-Australas J Anim Sci 2014 27 12 1783 1793 10.5713/ajas.2014.14720 25358373
Jeong JY, Suresh S, Park MN, Jang M, Park S, Gobianand K, et al. Effects of capsaicin on adipogenic differentiation in bovine bone marrow mesenchymal stem cell. Asian-Australas J Anim Sci. 2014;27(12):1783–93.25358373 10.5713/ajas.2014.14720
154. Montanari T Boschi F Colitti M Comparison of the effects of browning-inducing capsaicin on two murine adipocyte models Front Physiol 2019 10 1380 10.3389/fphys.2019.01380 31749714
Montanari T, Boschi F, Colitti M. Comparison of the effects of browning-inducing capsaicin on two murine adipocyte models. Front Physiol. 2019;10:1380.31749714 10.3389/fphys.2019.01380
155. Shin MK Yang SM Han IS Capsaicin suppresses liver fat accumulation in high-fat diet-induced NAFLD mice Anim Cells Syst (Seoul) 2020 24 4 214 219 10.1080/19768354.2020.1810771 33029298
Shin MK, Yang SM, Han IS. Capsaicin suppresses liver fat accumulation in high-fat diet-induced NAFLD mice. Anim Cells Syst (Seoul). 2020;24(4):214–9.33029298 10.1080/19768354.2020.1810771
156. Pande S Srinivasan K Potentiation of hypolipidemic and weight-reducing influence of dietary tender cluster bean (Cyamopsis tetragonoloba) when combined with capsaicin in high-fat-fed rats J Agric Food Chem 2012 60 33 8155 8162 10.1021/jf301211c 22835261
Pande S, Srinivasan K. Potentiation of hypolipidemic and weight-reducing influence of dietary tender cluster bean (Cyamopsis tetragonoloba) when combined with capsaicin in high-fat-fed rats. J Agric Food Chem. 2012;60(33):8155–62.22835261 10.1021/jf301211c
157. Mueller M Beck V Jungbauer A PPARα activation by culinary herbs and spices Planta Med 2011 77 5 497 504 10.1055/s-0030-1250435 20957597
Mueller M, Beck V, Jungbauer A. PPARα activation by culinary herbs and spices. Planta Med. 2011;77(5):497–504.20957597 10.1055/s-0030-1250435
158. Molloy JW Calcagno CJ Williams CD Jones FJ Torres DM Harrison SA Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis Hepatology 2012 55 2 429 436 10.1002/hep.24731 21987293
Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55(2):429–36.21987293 10.1002/hep.24731
159. Su SH Shyu HW Yeh YT Chen KM Yeh H Su SJ Caffeine inhibits adipogenic differentiation of primary adipose-derived stem cells and bone marrow stromal cells Toxicol In Vitro 2013 27 6 1830 1837 10.1016/j.tiv.2013.05.011 23727198
Su SH, Shyu HW, Yeh YT, Chen KM, Yeh H, Su SJ. Caffeine inhibits adipogenic differentiation of primary adipose-derived stem cells and bone marrow stromal cells. Toxicol In Vitro. 2013;27(6):1830–7.23727198 10.1016/j.tiv.2013.05.011
160. Zheng X Dai W Chen X Wang K Zhang W Liu L Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae J Biomed Sci 2015 22 105 10.1186/s12929-015-0206-3 26572131
Zheng X, Dai W, Chen X, Wang K, Zhang W, Liu L, et al. Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae. J Biomed Sci. 2015;22:105.26572131 10.1186/s12929-015-0206-3
161. Helal MG Ayoub SE Elkashefand WF Ibrahim TM Caffeine affects HFD-induced hepatic steatosis by multifactorial intervention Hum Exp Toxicol 2018 37 9 983 990 10.1177/0960327117747026 29249184
Helal MG, Ayoub SE, Elkashefand WF, Ibrahim TM. Caffeine affects HFD-induced hepatic steatosis by multifactorial intervention. Hum Exp Toxicol. 2018;37(9):983–90.29249184 10.1177/0960327117747026
162. Liu CW Tsai HC Huang CC Tsai CY Su YB Lin MW Effects and mechanisms of caffeine to improve immunological and metabolic abnormalities in diet-induced obese rats Am J Physiol Endocrinol Metab 2018 314 5 E433 E447 10.1152/ajpendo.00094.2017 29118012
Liu CW, Tsai HC, Huang CC, Tsai CY, Su YB, Lin MW, et al. Effects and mechanisms of caffeine to improve immunological and metabolic abnormalities in diet-induced obese rats. Am J Physiol Endocrinol Metab. 2018;314(5):E433–47.29118012 10.1152/ajpendo.00094.2017
163. Velickovic K Wayne D Leija HAL Bloor I Morris DE Law J Caffeine exposure induces browning features in adipose tissue in vitro and in vivo Sci Rep 2019 9 1 9104 10.1038/s41598-019-45540-1 31235722
Velickovic K, Wayne D, Leija HAL, Bloor I, Morris DE, Law J, et al. Caffeine exposure induces browning features in adipose tissue in vitro and in vivo. Sci Rep. 2019;9(1):9104.31235722 10.1038/s41598-019-45540-1
164. Velickovic K Lugo Leija HA Bloor I Law J Sacks H Symonds M Low temperature exposure induces browning of bone marrow stem cell derived adipocytes in vitro Sci Rep 2018 8 1 4974 10.1038/s41598-018-23267-9 29563605
Velickovic K, Lugo Leija HA, Bloor I, Law J, Sacks H, Symonds M, et al. Low temperature exposure induces browning of bone marrow stem cell derived adipocytes in vitro. Sci Rep. 2018;8(1):4974.29563605 10.1038/s41598-018-23267-9
165. Lv Z Xing K Li G Liu D Guo Y Dietary genistein alleviates lipid metabolism disorder and inflammatory response in laying hens with fatty liver syndrome Front Physiol 2018 9 1493 10.3389/fphys.2018.01493 30405443
Lv Z, Xing K, Li G, Liu D, Guo Y. Dietary genistein alleviates lipid metabolism disorder and inflammatory response in laying hens with fatty liver syndrome. Front Physiol. 2018;9:1493.30405443 10.3389/fphys.2018.01493
166. Qin H Song Z Shaukat H Zheng W Genistein regulates lipid metabolism via estrogen receptor β and its downstream signal Akt/mTOR in HepG2 Cells Nutrients 2021 13 11 10.3390/nu13114015
Qin H, Song Z, Shaukat H, Zheng W. Genistein regulates lipid metabolism via estrogen receptor β and its downstream signal Akt/mTOR in HepG2 Cells. Nutrients. 2021;13:11.10.3390/nu13114015
167. Kim MH Kang KS Lee YS The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease Br J Nutr 2010 104 9 1333 1342 10.1017/S0007114510002266 20687969
Kim MH, Kang KS, Lee YS. The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. Br J Nutr. 2010;104(9):1333–42.20687969 10.1017/S0007114510002266
168. Seidemann L Krüger A Kegel-Hübner V Seehofer D Damm G Influence of genistein on hepatic lipid metabolism in an in vitro model of hepatic steatosis Molecules 2021 26 4 10.3390/molecules26041156
Seidemann L, Krüger A, Kegel-Hübner V, Seehofer D, Damm G. Influence of genistein on hepatic lipid metabolism in an in vitro model of hepatic steatosis. Molecules. 2021;26:4.10.3390/molecules26041156
169. Xiao CWu Wood CM Weber D Aziz SA Mehta R Griffin P Cockell KA Dietary supplementation with soy isoflavones or replacement with soy proteins prevents hepatic lipid droplet accumulation and alters expression of genes involved in lipid metabolism in rats Genes Nutr 2014 9 1 10.1007/s12263-013-0373-3
Xiao CWu, Wood CM, Weber D, Aziz SA, Mehta R, Griffin P, Cockell KA, et al. Dietary supplementation with soy isoflavones or replacement with soy proteins prevents hepatic lipid droplet accumulation and alters expression of genes involved in lipid metabolism in rats. Genes Nutr. 2014;9:1.10.1007/s12263-013-0373-3
170. Tovar AR Murguía F Cruz CR Hernández-Pando R Fau - Aguilar-Salinas CA, Aguilar-Salinas Ca Fau - Pedraza-Chaverri J, Pedraza-Chaverri J Fau - Correa-Rotter R, A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephrotic syndrome J Nutr 2002 132 9 10.1093/jn/132.9.2562
Tovar AR, Murguía F, Cruz CR, Hernández-Pando R, Fau - Aguilar-Salinas CA, Aguilar-Salinas Ca Fau - Pedraza-Chaverri J, Pedraza-Chaverri J Fau - Correa-Rotter R, et al. A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephrotic syndrome. J Nutr. 2002;132:9.10.1093/jn/132.9.2562
171. Kuiper GG Lemmen JG Carlsson B Corton JC Safe SH van der Saag PT Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta Endocrinology 1998 139 10 4252 4263 10.1210/endo.139.10.6216 9751507
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139(10):4252–63.9751507 10.1210/endo.139.10.6216
172. Nie Q Xing M Hu J Hu X Nie S Xie M Metabolism and health effects of phyto-estrogens Crit Rev Food Sci Nutr 2017 57 11 2432 2454 10.1080/10408398.2015.1077194 26558495
Nie Q, Xing M, Hu J, Hu X, Nie S, Xie M. Metabolism and health effects of phyto-estrogens. Crit Rev Food Sci Nutr. 2017;57(11):2432–54.26558495 10.1080/10408398.2015.1077194
173. Tang G Xu Y Zhang C Wang N Li H Feng Y Green tea and epigallocatechin gallate (EGCG) for the management of nonalcoholic fatty liver diseases (NAFLD): insights into the role of oxidative stress and antioxidant mechanism Antioxidants 2021 10 7 10.3390/antiox10071076
Tang G, Xu Y, Zhang C, Wang N, Li H, Feng Y. Green tea and epigallocatechin gallate (EGCG) for the management of nonalcoholic fatty liver diseases (NAFLD): insights into the role of oxidative stress and antioxidant mechanism. Antioxidants. 2021;10:7.10.3390/antiox10071076
174. Yuan H Li Y Ling F Guan Y Zhang D Zhu Q The phytochemical epigallocatechin gallate prolongs the lifespan by improving lipid metabolism, reducing inflammation and oxidative stress in high-fat diet-fed obese rats Aging Cell 2020 19 9 e13199 10.1111/acel.13199 32729662
Yuan H, Li Y, Ling F, Guan Y, Zhang D, Zhu Q, et al. The phytochemical epigallocatechin gallate prolongs the lifespan by improving lipid metabolism, reducing inflammation and oxidative stress in high-fat diet-fed obese rats. Aging Cell. 2020;19(9): e13199.32729662 10.1111/acel.13199
175. Li Y Wu S Epigallocatechin gallate suppresses hepatic cholesterol synthesis by targeting SREBP-2 through SIRT1/FOXO1 signaling pathway Mol Cell Biochem 2018 448 1–2 175 185 10.1007/s11010-018-3324-x 29446047
Li Y, Wu S. Epigallocatechin gallate suppresses hepatic cholesterol synthesis by targeting SREBP-2 through SIRT1/FOXO1 signaling pathway. Mol Cell Biochem. 2018;448(1–2):175–85.29446047 10.1007/s11010-018-3324-x
176. Li Y Song Y Zhao M Guo Y Yu C Chen W A novel role for CRTC2 in hepatic cholesterol synthesis through SREBP-2 Hepatology (Baltimore, MD) 2017 66 2 481 497 10.1002/hep.29206 28395113
Li Y, Song Y, Zhao M, Guo Y, Yu C, Chen W, et al. A novel role for CRTC2 in hepatic cholesterol synthesis through SREBP-2. Hepatology (Baltimore, MD). 2017;66(2):481–97.28395113 10.1002/hep.29206
177. Lin L Zeng L Liu A Yuan D Peng Y Zhang S Role of epigallocatechin gallate in glucose, lipid, and protein metabolism and L-theanine in the metabolism-regulatory effects of epigallocatechin gallate Nutrients 2021 13 11 10.3390/nu13114120
Lin L, Zeng L, Liu A, Yuan D, Peng Y, Zhang S, et al. Role of epigallocatechin gallate in glucose, lipid, and protein metabolism and L-theanine in the metabolism-regulatory effects of epigallocatechin gallate. Nutrients. 2021;13:11.10.3390/nu13114120
178. Ding H Li Y Li W Tao H Liu L Zhang C Epigallocatechin-3-gallate activates the AMP-activated protein kinase signaling pathway to reduce lipid accumulation in canine hepatocytes J Cell Physiol 2021 236 1 405 416 10.1002/jcp.29869 32572960
Ding H, Li Y, Li W, Tao H, Liu L, Zhang C, et al. Epigallocatechin-3-gallate activates the AMP-activated protein kinase signaling pathway to reduce lipid accumulation in canine hepatocytes. J Cell Physiol. 2021;236(1):405–16.32572960 10.1002/jcp.29869
179. Kim HS Montana V Jang HJ Parpura V Kim JA Epigallocatechin gallate (EGCG) stimulates autophagy in vascular endothelial cells: a potential role for reducing lipid accumulation J Biol Chem 2013 288 31 22693 22705 10.1074/jbc.M113.477505 23754277
Kim HS, Montana V, Jang HJ, Parpura V, Kim JA. Epigallocatechin gallate (EGCG) stimulates autophagy in vascular endothelial cells: a potential role for reducing lipid accumulation. J Biol Chem. 2013;288(31):22693–705.23754277 10.1074/jbc.M113.477505
180. Li F Gao C Yan P Zhang M Wang Y Hu Y EGCG reduces obesity and white adipose tissue gain partly through AMPK activation in mice Front Pharmacol 2018 9 1366 10.3389/fphar.2018.01366 30524290
Li F, Gao C, Yan P, Zhang M, Wang Y, Hu Y, et al. EGCG reduces obesity and white adipose tissue gain partly through AMPK activation in mice. Front Pharmacol. 2018;9:1366.30524290 10.3389/fphar.2018.01366
181. Huang JB Zhang Y Zhou YB Wan XC Zhang JS Effects of epigallocatechin gallate on lipid metabolism and its underlying molecular mechanism in broiler chickens J Anim Physiol Anim Nutr 2015 99 4 719 727 10.1111/jpn.12276
Huang JB, Zhang Y, Zhou YB, Wan XC, Zhang JS. Effects of epigallocatechin gallate on lipid metabolism and its underlying molecular mechanism in broiler chickens. J Anim Physiol Anim Nutr. 2015;99(4):719–27.10.1111/jpn.12276
182. Naveed M Hejazi V Abbas M Kamboh AA Khan GJ Shumzaid M Chlorogenic acid (CGA): a pharmacological review and call for further research Biomed Pharmacother 2018 97 67 74 10.1016/j.biopha.2017.10.064 29080460
Naveed M, Hejazi V, Abbas M, Kamboh AA, Khan GJ, Shumzaid M, et al. Chlorogenic acid (CGA): a pharmacological review and call for further research. Biomed Pharmacother. 2018;97:67–74.29080460 10.1016/j.biopha.2017.10.064
183. Zhang LT Chang CQ Liu Y Chen ZM Effect of chlorogenic acid on disordered glucose and lipid metabolism in db/db mice and its mechanism Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2011 33 3 281 286 21718611
Zhang LT, Chang CQ, Liu Y, Chen ZM. Effect of chlorogenic acid on disordered glucose and lipid metabolism in db/db mice and its mechanism. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011;33(3):281–6.21718611
184. Gao X Zhu Z Bao Y Li Y Zhu W He X Chrysanthemum morifolium Ramat extract and probiotics combination ameliorates metabolic disorders through regulating gut microbiota and PPARα subcellular localization Chinese Med 2024 19 1 10.1186/s13020-024-00950-w
Gao X, Zhu Z, Bao Y, Li Y, Zhu W, He X, et al. Chrysanthemum morifolium Ramat extract and probiotics combination ameliorates metabolic disorders through regulating gut microbiota and PPARα subcellular localization. Chinese Med. 2024;19:1.10.1186/s13020-024-00950-w
185. Sudeep HV Venkatakrishna K Patel D Shyamprasad K Biomechanism of chlorogenic acid complex mediated plasma free fatty acid metabolism in rat liver BMC Complement Altern Med 2016 16 274 10.1186/s12906-016-1258-y 27495925
Sudeep HV, Venkatakrishna K, Patel D, Shyamprasad K. Biomechanism of chlorogenic acid complex mediated plasma free fatty acid metabolism in rat liver. BMC Complement Altern Med. 2016;16:274.27495925 10.1186/s12906-016-1258-y
186. Cho AS Jeon SM Kim MJ Yeo J Seo KI Choi MS Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice Food Chem Toxicol 2010 48 3 937 943 10.1016/j.fct.2010.01.003 20064576
Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, Choi MS, et al. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010;48(3):937–43.20064576 10.1016/j.fct.2010.01.003
187. Zhou Y Ruan Z Wen Y Yang Y Mi S Zhou L Chlorogenic acid from honeysuckle improves hepatic lipid dysregulation and modulates hepatic fatty acid composition in rats with chronic endotoxin infusion J Clin Biochem Nutr 2016 58 2 146 155 10.3164/jcbn.14-138 27013782
Zhou Y, Ruan Z, Wen Y, Yang Y, Mi S, Zhou L, et al. Chlorogenic acid from honeysuckle improves hepatic lipid dysregulation and modulates hepatic fatty acid composition in rats with chronic endotoxin infusion. J Clin Biochem Nutr. 2016;58(2):146–55.27013782 10.3164/jcbn.14-138
188. Mubarak A Hodgson JM Considine MJ Croft KD Matthews VB Supplementation of a high-fat diet with chlorogenic acid is associated with insulin resistance and hepatic lipid accumulation in mice J Agric Food Chem 2013 61 18 4371 4378 10.1021/jf400920x 23586419
Mubarak A, Hodgson JM, Considine MJ, Croft KD, Matthews VB. Supplementation of a high-fat diet with chlorogenic acid is associated with insulin resistance and hepatic lipid accumulation in mice. J Agric Food Chem. 2013;61(18):4371–8.23586419 10.1021/jf400920x
189. Yan Y Li Q Shen L Guo K Zhou X Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice Front Endocrinol (Lausanne) 2022 13 1042044 10.3389/fendo.2022.1042044 36465648
Yan Y, Li Q, Shen L, Guo K, Zhou X. Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice. Front Endocrinol (Lausanne). 2022;13:1042044.36465648 10.3389/fendo.2022.1042044
190. Wang Y Peng S Mei Z Jin C Kang J Xiang M Chlorogenic acid inhibits forming of diabetes mellitus in rats induced by high-fat high-sucrose and streptozotocin Pak J Pharm Sci 2020 33 3 1063 1072 33191230
Wang Y, Peng S, Mei Z, Jin C, Kang J, Xiang M, et al. Chlorogenic acid inhibits forming of diabetes mellitus in rats induced by high-fat high-sucrose and streptozotocin. Pak J Pharm Sci. 2020;33(3):1063–72.33191230
191. Peng SG Pang YL Zhu Q Kang JH Liu MX Wang Z Chlorogenic acid functions as a novel agonist of PPARγ2 during the differentiation of mouse 3T3-L1 Preadipocytes Biomed Res Int 2018 2018 8594767 10.1155/2018/8594767 30627576
Peng SG, Pang YL, Zhu Q, Kang JH, Liu MX, Wang Z. Chlorogenic acid functions as a novel agonist of PPARγ2 during the differentiation of mouse 3T3-L1 Preadipocytes. Biomed Res Int. 2018;2018:8594767.30627576 10.1155/2018/8594767
192. Yao R Wang M Zhao Y Ji Q Feng X Bai L Chlorogenic acid enhances PPARγ -mediated lipogenesis through preventing Lipin 1 nuclear translocation in Staphylococcus aureus -exposed bovine mammary epithelial cells Biochimica Et Biophysica Acta-Mol Cell Biol Lipids 2023 1868 11
Yao R, Wang M, Zhao Y, Ji Q, Feng X, Bai L, et al. Chlorogenic acid enhances PPARγ -mediated lipogenesis through preventing Lipin 1 nuclear translocation in Staphylococcus aureus -exposed bovine mammary epithelial cells. Biochimica Et Biophysica Acta-Mol Cell Biol Lipids. 2023;1868:11.
193. Choi YR Kim YS Kim MJ Cinnamyl alcohol attenuates adipogenesis in 3T3-L1 cells by arresting the cell cycle Int J Mol Sci 2024 25 2 10.3390/ijms25020693
Choi YR, Kim YS, Kim MJ. Cinnamyl alcohol attenuates adipogenesis in 3T3-L1 cells by arresting the cell cycle. Int J Mol Sci. 2024;25:2.10.3390/ijms25020693
194. Arumugam MK Paal MC Donohue TM Jr Ganesan M Osna NA Kharbanda KK Beneficial effects of betaine a comprehensive review Biology 2021 10 6 10.3390/biology10060456
Arumugam MK, Paal MC, Donohue TM Jr, Ganesan M, Osna NA, Kharbanda KK. Beneficial effects of betaine a comprehensive review. Biology. 2021;10:6.10.3390/biology10060456
195. Yang W Huang L Gao J Wen S Tai Y Chen M Betaine attenuates chronic alcohol-induced fatty liver by broadly regulating hepatic lipid metabolism Mol Med Rep 2017 16 4 5225 5234 10.3892/mmr.2017.7295 28849079
Yang W, Huang L, Gao J, Wen S, Tai Y, Chen M, et al. Betaine attenuates chronic alcohol-induced fatty liver by broadly regulating hepatic lipid metabolism. Mol Med Rep. 2017;16(4):5225–34.28849079 10.3892/mmr.2017.7295
196. Dou X Xia Y Chen J Qian Y Li S Zhang X Rectification of impaired adipose tissue methylation status and lipolytic response contributes to hepatoprotective effect of betaine in a mouse model of alcoholic liver disease Br J Pharmacol 2014 171 17 4073 4086 10.1111/bph.12765 24819676
Dou X, Xia Y, Chen J, Qian Y, Li S, Zhang X, et al. Rectification of impaired adipose tissue methylation status and lipolytic response contributes to hepatoprotective effect of betaine in a mouse model of alcoholic liver disease. Br J Pharmacol. 2014;171(17):4073–86.24819676 10.1111/bph.12765
197. Yang W Gao J Tai Y Chen M Huang L Wen S Betaine attenuates alcohol-induced pancreatic steatosis Pancreas 2016 45 6 836 845 10.1097/MPA.0000000000000557 26646265
Yang W, Gao J, Tai Y, Chen M, Huang L, Wen S, et al. Betaine attenuates alcohol-induced pancreatic steatosis. Pancreas. 2016;45(6):836–45.26646265 10.1097/MPA.0000000000000557
198. Mackowiak B Fu Y Maccioni L Gao B Alcohol-associated liver disease J Clin Investigat 2024 134 3 10.1172/JCI176345
Mackowiak B, Fu Y, Maccioni L, Gao B. Alcohol-associated liver disease. J Clin Investigat. 2024;134:3.10.1172/JCI176345
199. Liu J Song R Su S Qi N Li Q Xie Z Betaine promotes fat accumulation and reduces injury in landes goose hepatocytes by regulating multiple lipid metabolism pathways Animals 2022 12 12
Liu J, Song R, Su S, Qi N, Li Q, Xie Z, et al. Betaine promotes fat accumulation and reduces injury in landes goose hepatocytes by regulating multiple lipid metabolism pathways. Animals. 2022;12:12.
200. Xu L Huang D Hu Q Wu J Wang Y Feng J Betaine alleviates hepatic lipid accumulation via enhancing hepatic lipid export and fatty acid oxidation in rats fed with a high-fat diet Br J Nutr 2015 113 12 1835 1843 10.1017/S0007114515001130 25920593
Xu L, Huang D, Hu Q, Wu J, Wang Y, Feng J. Betaine alleviates hepatic lipid accumulation via enhancing hepatic lipid export and fatty acid oxidation in rats fed with a high-fat diet. Br J Nutr. 2015;113(12):1835–43.25920593 10.1017/S0007114515001130
201. Adjoumani JY Wang K Zhou M Liu W Zhang D Effect of dietary betaine on growth performance, antioxidant capacity and lipid metabolism in blunt snout bream fed a high-fat diet Fish Physiol Biochem 2017 43 6 1733 1745 10.1007/s10695-017-0405-9 28963592
Adjoumani JY, Wang K, Zhou M, Liu W, Zhang D. Effect of dietary betaine on growth performance, antioxidant capacity and lipid metabolism in blunt snout bream fed a high-fat diet. Fish Physiol Biochem. 2017;43(6):1733–45.28963592 10.1007/s10695-017-0405-9
202. Chen W Zhang X Xu M Jiang L Zhou M Liu W Betaine prevented high-fat diet-induced NAFLD by regulating the FGF10/AMPK signaling pathway in ApoE(-/-) mice Eur J Nutr 2021 60 3 1655 1668 10.1007/s00394-020-02362-6 32808060
Chen W, Zhang X, Xu M, Jiang L, Zhou M, Liu W, et al. Betaine prevented high-fat diet-induced NAFLD by regulating the FGF10/AMPK signaling pathway in ApoE(-/-) mice. Eur J Nutr. 2021;60(3):1655–68.32808060 10.1007/s00394-020-02362-6
203. Zhou P Xie W He S Sun Y Meng X Sun G Ginsenoside Rb1 as an anti-diabetic agent and its underlying mechanism analysis Cells 2019 8 3 10.3390/cells8030204
Zhou P, Xie W, He S, Sun Y, Meng X, Sun G, et al. Ginsenoside Rb1 as an anti-diabetic agent and its underlying mechanism analysis. Cells. 2019;8:3.10.3390/cells8030204
204. Fan Q Xi P Tian D Jia L Cao Y Zhan K Ginsenoside Rb1 facilitates browning by repressing Wnt/β-catenin signaling in 3T3-L1 adipocytes Med Sci Monit 2021 27 e928619 10.12659/MSM.928619 33503016
Fan Q, Xi P, Tian D, Jia L, Cao Y, Zhan K, et al. Ginsenoside Rb1 facilitates browning by repressing Wnt/β-catenin signaling in 3T3-L1 adipocytes. Med Sci Monit. 2021;27: e928619.33503016 10.12659/MSM.928619
205. Hou Y Gu D Peng J Jiang K Li Z Shi J Ginsenoside Rg1 regulates liver lipid factor metabolism in NAFLD model rats ACS Omega 2020 5 19 10878 10890 10.1021/acsomega.0c00529 32455208
Hou Y, Gu D, Peng J, Jiang K, Li Z, Shi J, et al. Ginsenoside Rg1 regulates liver lipid factor metabolism in NAFLD model rats. ACS Omega. 2020;5(19):10878–90.32455208 10.1021/acsomega.0c00529
206. Qiao L Zhang X Liu M Liu X Dong M Cheng J Ginsenoside Rb1 enhances atherosclerotic plaque stability by improving autophagy and lipid metabolism in macrophage foam cells Front Pharmacol 2017 8 727 10.3389/fphar.2017.00727 29114222
Qiao L, Zhang X, Liu M, Liu X, Dong M, Cheng J, et al. Ginsenoside Rb1 enhances atherosclerotic plaque stability by improving autophagy and lipid metabolism in macrophage foam cells. Front Pharmacol. 2017;8:727.29114222 10.3389/fphar.2017.00727
207. Hwang JT Lee MS Kim HJ Sung MJ Kim HY Kim MS Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways Phytotherapy Res 2009 23 2 262 266 10.1002/ptr.2606
Hwang JT, Lee MS, Kim HJ, Sung MJ, Kim HY, Kim MS, et al. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytotherapy Res. 2009;23(2):262–6.10.1002/ptr.2606
208. Quan HY Yuan HD Jung MS Ko SK Park YG Chung SH Ginsenoside Re lowers blood glucose and lipid levels via activation of AMP-activated protein kinase in HepG2 cells and high-fat diet fed mice Int J Mol Med 2012 29 1 73 80 21971952
Quan HY, Yuan HD, Jung MS, Ko SK, Park YG, Chung SH. Ginsenoside Re lowers blood glucose and lipid levels via activation of AMP-activated protein kinase in HepG2 cells and high-fat diet fed mice. Int J Mol Med. 2012;29(1):73–80.21971952
209. Li G Xu Y Gao Q Guo S Zu Y Wang X Ginsenosides restore lipid and redox homeostasis in mice with intrahepatic cholestasis through SIRT1/AMPK pathways Nutrients 2022 14 19
Li G, Xu Y, Gao Q, Guo S, Zu Y, Wang X, et al. Ginsenosides restore lipid and redox homeostasis in mice with intrahepatic cholestasis through SIRT1/AMPK pathways. Nutrients. 2022;14:19.
210. Oh JM Chun S Ginsenoside CK inhibits the early stage of adipogenesis via the AMPK, MAPK, and AKT signaling pathways Antioxidants 2022 11 10 10.3390/antiox11101890
Oh JM, Chun S. Ginsenoside CK inhibits the early stage of adipogenesis via the AMPK, MAPK, and AKT signaling pathways. Antioxidants. 2022;11:10.10.3390/antiox11101890
211. Huang YC Lin CY Huang SF Lin HC Chang WL Chang TC Effect and mechanism of ginsenosides CK and Rg1 on stimulation of glucose uptake in 3T3-L1 adipocytes J Agric Food Chem 2010 58 10 6039 6047 10.1021/jf9034755 20441170
Huang YC, Lin CY, Huang SF, Lin HC, Chang WL, Chang TC. Effect and mechanism of ginsenosides CK and Rg1 on stimulation of glucose uptake in 3T3-L1 adipocytes. J Agric Food Chem. 2010;58(10):6039–47.20441170 10.1021/jf9034755
212. Hwang JT Lee MS Kim HJ Sung MJ Kim HY Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways Phytother Res 2009 23 2 10.1002/ptr.2606
Hwang JT, Lee MS, Kim HJ, Sung MJ, Kim HY, et al. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytother Res. 2009;23:2.10.1002/ptr.2606
213. Lee S Lee MS Kim CT Kim IH Kim Y Ginsenoside Rg3 reduces lipid accumulation with AMP-activated protein kinase (AMPK) activation in HepG2 cells Int J Mol Sci 2012 13 5 5729 5739 10.3390/ijms13055729 22754327
Lee S, Lee MS, Kim CT, Kim IH, Kim Y. Ginsenoside Rg3 reduces lipid accumulation with AMP-activated protein kinase (AMPK) activation in HepG2 cells. Int J Mol Sci. 2012;13(5):5729–39.22754327 10.3390/ijms13055729
214. Gu W Kim KA Kim DH Ginsenoside Rh1 ameliorates high fat diet-induced obesity in mice by inhibiting adipocyte differentiation Biol Pharm Bull 2013 36 1 102 107 10.1248/bpb.b12-00558 23302642
Gu W, Kim KA, Kim DH. Ginsenoside Rh1 ameliorates high fat diet-induced obesity in mice by inhibiting adipocyte differentiation. Biol Pharm Bull. 2013;36(1):102–7.23302642 10.1248/bpb.b12-00558
215. Liu H Liu M Jin Z Yaqoob S Zheng M Cai D Ginsenoside Rg2 inhibits adipogenesis in 3T3-L1 preadipocytes and suppresses obesity in high-fat-diet-induced obese mice through the AMPK pathway Food Funct 2019 10 6 3603 3614 10.1039/C9FO00027E 31161181
Liu H, Liu M, Jin Z, Yaqoob S, Zheng M, Cai D, et al. Ginsenoside Rg2 inhibits adipogenesis in 3T3-L1 preadipocytes and suppresses obesity in high-fat-diet-induced obese mice through the AMPK pathway. Food Funct. 2019;10(6):3603–14.31161181 10.1039/C9FO00027E
216. Gao Y Zhang S Li J Zhao J Xiao Q Zhu Y Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid Biosci Biotechnol Biochem 2020 84 11 2228 2240 10.1080/09168451.2020.1793293 32654591
Gao Y, Zhang S, Li J, Zhao J, Xiao Q, Zhu Y, et al. Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid. Biosci Biotechnol Biochem. 2020;84(11):2228–40.32654591 10.1080/09168451.2020.1793293
217. Siraj FM SathishKumar N Kim YJ Kim SY Yang DC Ginsenoside F2 possesses anti-obesity activity via binding with PPARγ and inhibiting adipocyte differentiation in the 3T3-L1 cell line J Enzyme Inhib Med Chem 2015 30 1 9 14 10.3109/14756366.2013.871006 24666293
Siraj FM, SathishKumar N, Kim YJ, Kim SY, Yang DC. Ginsenoside F2 possesses anti-obesity activity via binding with PPARγ and inhibiting adipocyte differentiation in the 3T3-L1 cell line. J Enzyme Inhib Med Chem. 2015;30(1):9–14.24666293 10.3109/14756366.2013.871006
218. Liu Z Liao W Yin X Zheng X Li Q Zhang H Resveratrol-induced brown fat-like phenotype in 3T3-L1 adipocytes partly via mTOR pathway Food Nutr Res 2020 64 1 10.29219/fnr.v64.3656
Liu Z, Liao W, Yin X, Zheng X, Li Q, Zhang H, et al. Resveratrol-induced brown fat-like phenotype in 3T3-L1 adipocytes partly via mTOR pathway. Food Nutr Res. 2020;64:1.10.29219/fnr.v64.3656
219. Wang S Liang X Yang Q Fu X Zhu M Rodgers BD Resveratrol enhances brown adipocyte formation and function by activating AMP-activated protein kinase (AMPK) α1 in mice fed high-fat diet Mol Nutr Food Res 2017 61 4 10.1002/mnfr.201600746
Wang S, Liang X, Yang Q, Fu X, Zhu M, Rodgers BD, et al. Resveratrol enhances brown adipocyte formation and function by activating AMP-activated protein kinase (AMPK) α1 in mice fed high-fat diet. Mol Nutr Food Res. 2017;61:4.10.1002/mnfr.201600746
220. Cho SJ Jung UJ Choi MS Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice Br J Nutr 2012 108 12 2166 2175 10.1017/S0007114512000347 22414733
Cho SJ, Jung UJ, Choi MS. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br J Nutr. 2012;108(12):2166–75.22414733 10.1017/S0007114512000347
221. Jing Y Hu T Lin C Xiong Q Liu F Yuan J Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor α-mediated pathway in L02 cells Eur J Pharmacol 2019 855 216 226 10.1016/j.ejphar.2019.05.019 31085239
Jing Y, Hu T, Lin C, Xiong Q, Liu F, Yuan J, et al. Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor α-mediated pathway in L02 cells. Eur J Pharmacol. 2019;855:216–26.31085239 10.1016/j.ejphar.2019.05.019
222. Zhou R Yi L Ye X Zeng X Liu K Qin Y Resveratrol ameliorates lipid droplet accumulation in liver through a SIRT1/ ATF6-dependent mechanism Cell Physiol Biochem 2018 51 5 2397 2420 10.1159/000495898 30537742
Zhou R, Yi L, Ye X, Zeng X, Liu K, Qin Y, et al. Resveratrol ameliorates lipid droplet accumulation in liver through a SIRT1/ ATF6-dependent mechanism. Cell Physiol Biochem. 2018;51(5):2397–420.30537742 10.1159/000495898
223. Tang LY Chen Y Rui BB Hu CM Resveratrol ameliorates lipid accumulation in HepG2 cells, associated with down-regulation of lipin1 expression Can J Physiol Pharmacol 2016 94 2 185 189 10.1139/cjpp-2015-0125 26448098
Tang LY, Chen Y, Rui BB, Hu CM. Resveratrol ameliorates lipid accumulation in HepG2 cells, associated with down-regulation of lipin1 expression. Can J Physiol Pharmacol. 2016;94(2):185–9.26448098 10.1139/cjpp-2015-0125
224. Wang C Yuan Y Li L Zhang XM Li J Hu PZ Effects of resveratrol on the morphology of lipid droplets and the expression of lipid droplet-associated proteins in mouse primary hepatocytes Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012 28 9 911 914 22980652
Wang C, Yuan Y, Li L, Zhang XM, Li J, Hu PZ, et al. Effects of resveratrol on the morphology of lipid droplets and the expression of lipid droplet-associated proteins in mouse primary hepatocytes. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012;28(9):911–4.22980652
225. Nishikawa K Iwaya K Kinoshita M Fujiwara Y Akao M Sonoda M Resveratrol increases CD68+ Kupffer cells colocalized with adipose differentiation-related protein and ameliorates high-fat-diet-induced fatty liver in mice Mol Nutr Food Res 2015 59 6 1155 1170 10.1002/mnfr.201400564 25677089
Nishikawa K, Iwaya K, Kinoshita M, Fujiwara Y, Akao M, Sonoda M, et al. Resveratrol increases CD68+ Kupffer cells colocalized with adipose differentiation-related protein and ameliorates high-fat-diet-induced fatty liver in mice. Mol Nutr Food Res. 2015;59(6):1155–70.25677089 10.1002/mnfr.201400564
226. Ma Q Shen M Wu J Ye C Tan Y Mechanism research of DHEA treatment improving diminished ovarian reserve by attenuating the AMPK-SIRT1 signaling and mitophagy Reproductive Sci 2024 1 14
Ma Q, Shen M, Wu J, Ye C, Tan Y. Mechanism research of DHEA treatment improving diminished ovarian reserve by attenuating the AMPK-SIRT1 signaling and mitophagy. Reproductive Sci. 2024;1:14.
227. Zhou R Yi L Ye X Zeng X Liu K Qin Y Resveratrol ameliorates lipid droplet accumulation in liver through a SIRT1/ATF6-dependent mechanism Cell Physiol Biochem 2018 51 5 2397 2420 10.1159/000495898 30537742
Zhou R, Yi L, Ye X, Zeng X, Liu K, Qin Y, et al. Resveratrol ameliorates lipid droplet accumulation in liver through a SIRT1/ATF6-dependent mechanism. Cell Physiol Biochem. 2018;51(5):2397–420.30537742 10.1159/000495898
228. Chang N Li J Lin S Zhang J Zeng W Ma G Emerging roles of SIRT1 activator, SRT2104, in disease treatment Sci Rep 2024 14 1 5521 10.1038/s41598-024-55923-8 38448466
Chang N, Li J, Lin S, Zhang J, Zeng W, Ma G, et al. Emerging roles of SIRT1 activator, SRT2104, in disease treatment. Sci Rep. 2024;14(1):5521.38448466 10.1038/s41598-024-55923-8
229. Mehdi F Keihan GS Asadollah AS Effat F The effects of resveratrol, metformin, cold and strength training on the level of perilipin 5 in the heart, skeletal muscle and brown adipose tissues in mouse Cell Biochem Biophys 2018 76 4 471 476 10.1007/s12013-018-0860-7 30343407
Mehdi F, Keihan GS, Asadollah AS, Effat F. The effects of resveratrol, metformin, cold and strength training on the level of perilipin 5 in the heart, skeletal muscle and brown adipose tissues in mouse. Cell Biochem Biophys. 2018;76(4):471–6.30343407 10.1007/s12013-018-0860-7
230. van Polanen N Zacharewicz E de Ligt M Timmers S Moonen-Kornips E Schaart G Resveratrol-induced remodelling of myocellular lipid stores: a study in metabolically compromised humans Physiol Rep 2021 9 2 e14692 10.14814/phy2.14692 33476086
van Polanen N, Zacharewicz E, de Ligt M, Timmers S, Moonen-Kornips E, Schaart G, et al. Resveratrol-induced remodelling of myocellular lipid stores: a study in metabolically compromised humans. Physiol Rep. 2021;9(2): e14692.33476086 10.14814/phy2.14692
231. Calle RA Amin NB Carvajal-Gonzalez S Ross TT Bergman A Aggarwal S ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials Nat Med 2021 27 10 1836 1848 10.1038/s41591-021-01489-1 34635855
Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, Aggarwal S, et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med. 2021;27(10):1836–48.34635855 10.1038/s41591-021-01489-1
232. Yue S Li J Lee SY Lee HJ Shao T Song B Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness Cell Metab 2014 19 3 393 406 10.1016/j.cmet.2014.01.019 24606897
Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014;19(3):393–406.24606897 10.1016/j.cmet.2014.01.019
233. Donnerer J Amann R Schuligoi R Lembeck F Absorption and metabolism of capsaicinoids following intragastric administration in rats Naunyn Schmiedebergs Arch Pharmacol 1990 342 3 357 361 10.1007/BF00169449 2280802
Donnerer J, Amann R, Schuligoi R, Lembeck F. Absorption and metabolism of capsaicinoids following intragastric administration in rats. Naunyn Schmiedebergs Arch Pharmacol. 1990;342(3):357–61.2280802 10.1007/BF00169449
234. Kawada T Watanabe T Katsura K Takami H Iwai K Formation and metabolism of pungent principle of capsicum fruits. XV. Microdetermination of capsaicin by high-performance liquid chromatography with electrochemical detection J Chromato A 1985 329 99 105 10.1016/S0021-9673(01)81899-9
Kawada T, Watanabe T, Katsura K, Takami H, Iwai K. Formation and metabolism of pungent principle of capsicum fruits. XV. Microdetermination of capsaicin by high-performance liquid chromatography with electrochemical detection. J Chromato A. 1985;329:99–105.10.1016/S0021-9673(01)81899-9
235. Yu Q Li M Chen H Xu L Cheng J Lin G The discovery of berberine erythrocyte-hemoglobin self-assembly delivery system: a neglected carrier underlying its pharmacokinetics Drug Delivery 2022 29 1 856 870 10.1080/10717544.2022.2036870 35277093
Yu Q, Li M, Chen H, Xu L, Cheng J, Lin G, et al. The discovery of berberine erythrocyte-hemoglobin self-assembly delivery system: a neglected carrier underlying its pharmacokinetics. Drug Delivery. 2022;29(1):856–70.35277093 10.1080/10717544.2022.2036870
236. Coppinger C Pomales B Movahed MR Marefat M Hashemzadeh M Berberine: a multi-target natural PCSK9 inhibitor with the potential to treat diabetes, alzheimer's, cancer and cardiovascular disease Curr Rev Clin Exp Pharmacol 2024 19 4 10.2174/0127724328250471231222094648
Coppinger C, Pomales B, Movahed MR, Marefat M, Hashemzadeh M. Berberine: a multi-target natural PCSK9 inhibitor with the potential to treat diabetes, alzheimer’s, cancer and cardiovascular disease. Curr Rev Clin Exp Pharmacol. 2024;19:4.10.2174/0127724328250471231222094648
237. Hao S, Xiao Y, Lin Y, Mo Z, Chen Y, Peng X, et al. Chlorogenic acid-enriched extract from Eucommia ulmoides leaves inhibits hepatic lipid accumulation through regulation of cholesterol metabolism in HepG2 cells. Pharm Biol. 2016;54(2):251–9.
238. Hong Y, Feng J, Dou Z, Sun X, Hu Y, Chen Z, et al. Berberine as a novel ACSL4 inhibitor to suppress endothelial ferroptosis and atherosclerosis. Biomed Pharmacother. 2024;177:117081.
239. Hu YH, Han J, Wang L, Shi C, Li Y, Olatunji OJ, et al. α-Mangostin Alleviated Inflammation in Rats With Adjuvant-Induced Arthritis by Disrupting Adipocytes-Mediated Metabolism-Immune Feedback. Front Pharmacol. 2021;12:692806.
240. Sanchez MB, Miranda-Perez E, Verjan JCG, de Los Angeles Fortis Barrera M, Perez-Ramos J, Alarcon-Aguilar FJ. Potential of the chlorogenic acid as multitarget agent: Insulin-secretagogue and PPAR α/γ dual agonist. Biomed Pharmacother. 2017;94:169–75.
241. Yao R, Wang M, Zhao Y, Ji Q, Feng X, Bai L, et al. Chlorogenic acid enhances PPARγ-mediated lipogenesis through preventing Lipin 1 nuclear translocation in Staphylococcus aureus-exposed bovine mammary epithelial cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2023;1868(11):159396.
242. Yuanyuan Z, Huaizhen L. Mechanistic research into the effects of the Jianpi Xiaozhi formula on liver injury in diabetic rats. Evid Based Complement Alternat Med. 2022;2022:7490747.
243. Zhang L, Zheng YL, Hu RH, Zhu L, Hu CC, Cheng F, et al. Annexin A1 mimetic peptide AC2-26 inhibits sepsis-induced cardiomyocyte apoptosis through LXA4/PI3K/AKT signaling pathway. Curr Med Sci. 2018;38(6):997–1004.
244. Zhong H, Chen K, Feng M, Shao W, Wu J, Chen K, et al. Genipin alleviates high-fat diet-induced hyperlipidemia and hepatic lipid accumulation in mice via miR-142a-5p/SREBP-1c axis. FEBS J. 2018;285(3):501–17.
